

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Adolescent and Young Adult (AYA) Oncology

Version 2.2018 — October 11, 2017

NCCN.org

NCCN Guidelines for Patients® available at www.nccn.org/patients

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018 Panel Members

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

* Peter F. Coccia, MD/Chair € ‡ ξ
Fred & Pamela Buffett Cancer Center

* Alberto S. Pappo, MD/Vice Chair € ‡
St. Jude Children's Research Hospital/
University of Tennessee Health Science Center

* Lynda Beaupin, MD €
Roswell Park Cancer Institute

Virginia F. Borges, MD, MMSc †
University of Colorado Cancer Center

* Scott C. Borinstein, MD, PhD € ‡
Vanderbilt-Ingram Cancer Center

Rashmi Chugh, MD ‡ †
University of Michigan
Comprehensive Cancer Center

Shira Dinner, MD † ‡ ξ
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Jeanette Folbrecht, PhD θ £
City of Hope Comprehensive Cancer Center

A. Lindsay Frazier, MD, ScM € ‡
Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center

Robert Goldsby, MD €
UCSF Helen Diller Family
Comprehensive Cancer Center

* Alexandra Gubin, MSW, LCSW-C £
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

* Robert Hayashi, MD € ‡ ξ
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Mary S. Huang, MD € ‡
Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center

Michael P. Link, MD €
Stanford Cancer Institute

John A. Livingston, MD †‡
The University of Texas
MD Anderson Cancer Center

Yousif Matloub, MD €
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Center

Frederick Millard, MD †
UC San Diego Moores Cancer Center

Kevin C. Oeffinger, MD † θ
Duke Cancer Institute

* Diane Puccetti, MD €
University of Wisconsin
Carbone Cancer Center

* Damon Reed, MD € ‡
Moffitt Cancer Center

Steven Robinson, MBBS †
Mayo Clinic Cancer Center

* Abby R. Rosenberg, MD, MS € ‡ £
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Tara Sanft, MD †
Yale Cancer Center/Smilow Cancer Hospital

Holly L. Spraker-Perlman, MD, MS € ‡ θ
Huntsman Cancer Institute
at the University of Utah

Margaret von Mehren, MD †
Fox Chase Cancer Center

* Daniel S. Wechsler, MD, PhD € ‡
Duke Cancer Institute

Kimberly F. Whelan, MD € ‡
University of Alabama at Birmingham
Comprehensive Cancer Center

Nicholas Yeager, MD €
The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute

NCCN
Lisa Gurski, PhD
Dorothy A. Shead, MS

Continue

[NCCN Guidelines Panel Disclosures](#)

* Writing committee	€ Pediatric oncology
ξ Bone marrow transplantation	θ Psychiatry and psychology, including health behavior
Δ Cancer genetics	£ Supportive care including palliative, pain management, pastoral care, and oncology social work
‡ Hematology/Hematology oncology	
‡ Internal medicine	
† Medical oncology	



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018 Table of Contents

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

[NCCN Guidelines AYAO Panel Members](#)

[Summary of Updates](#)

[Definition of the AYA Population and Purpose of the NCCN Guidelines for AYA Oncology \(AYAO-1\)](#)

[Screening, Assessment, and Evaluation \(AYAO-2\)](#)

[Comprehensive Assessment \(AYAO-3\)](#)

[Age-Appropriate Care \(AYAO-4\)](#)

[Treatment-Related Issues \(AYAO-5\)](#)

[Fertility/Endocrine Considerations \(AYAO-6\)](#)

[Psychosocial/Behavioral Considerations:](#)

- [Individual \(AYAO-7\)](#)
- [Relationships \(AYAO-9\)](#)
- [Socioeconomic Issues \(AYAO-10\)](#)

[Survivorship \(AYAO-11\)](#)

[Disease-Specific Issues Related to Age \(AYAO-A\)](#)

[Screening Recommendations for AYA Survivors \(AYAO-B\)](#)

[Palliative Care and End-of-Life Considerations \(AYAO-C\)](#)

[Online Resources for AYA Patients and Survivors \(AYAO-D\)](#)

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/physician.html](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.



NCCN Guidelines Version 2.2018 Updates Adolescent and Young Adult Oncology

Updates in Version 2.2018 of the NCCN Guidelines for Adolescent and Young Adult Oncology from Version 1.2018 include:

[MS-1](#)

- The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2018 of the NCCN Guidelines for Adolescent and Young Adult Oncology from Version 2.2017 include:

[AYAO-1](#)

- Added "Adolescents and young adult patients with cancer have a number of unique psychosocial concerns that have been identified by panels of experts, including (although not limited to) fertility preservation, parenting, schooling, employment attainment, and retention. The relative importance of these issues understandably varies markedly across the broad age range defined. These issues should be considered as part of the overall therapeutic plan for the patient. Specific recommendations are highlighted in the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology. Many centers have established AYA centers to accommodate the specific needs of patients with cancer in this age group. Consideration should be given to referring such patients to one of these AYA centers of excellence if feasible."
- Purpose of the NCCN Guidelines for AYA Oncology, modified the last sentence. "Participation in clinical trials *as well as enrollment on tumor banking and biologic protocols* should be strongly encouraged in the AYA population."

[AYAO-2](#)

- Removed, "AYA patients usually tolerate more intensive therapies than older patients." Modified the last sentence, "Treatment approaches will vary depending on *initial* diagnosis."
- Modified, "Strongly consider a referral for treatment at a cancer center with expertise in treatment of AYAs with cancer, and have access to clinical trials for AYAs, *particularly for pediatric cancer types*."
- Replaced link to Socioeconomic issues (AYAO-9) with a link to Psychosocial/Behavioral Considerations (AYAO-7 and AYAO-8).

[AYAO-3](#)

- New bullet: "All women of child-bearing potential must receive a pregnancy test prior to initiating therapy."
- Modified: "Discuss risks of infertility due to cancer and its therapy, as *well as options for fertility preservation*."

- Modified: "*Recommend* referral for genetic and familial risk assessment/counseling *as appropriate based on clinical/family history and histologic diagnosis* (~~within 2 months after the start of therapy~~)."

[AYAO-4](#)

- Updated table data and reference.

[AYAO-5](#)

- Changed: "AYA patients usually..." to "*Selected AYA patients may* tolerate more intensive therapies than older patients."
- Modified: "Monitoring of cumulative dosing *and schedule* for certain medications associated with irreversible organ damage *and fertility issues* may be essential when certain lifetime exposure is encountered."
- Replaced list of agents with a link to See AYAO-11 for specific agents."
- Modified: "~~Intensive~~ screening is recommended for the following treatment-related toxicities."
- Cardiac toxicity, added the following sentence "*Recommend adding cardioprotectant (eg, dexrazoxane) for patients receiving an anthracycline*."

[AYAO-6](#)

- Modified: "Discuss risks for infertility due to cancer and its therapy (*especially for high-risk therapies such as alkylating agents or gonadal irradiation*), fertility preservation, and contraception prior to the start of therapy."
- Males: changed wording, "Discuss the ~~possibility~~ option of sperm banking."
- Females: changed wording, "Discuss the ~~possibility~~ option of embryo or oocyte cryopreservation or ovarian tissue cryopreservation (*if available*)"
- Males and Females: added: "*Consider follow-up with fertility specialist post-treatment*."

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

Updates in Version 1.2018 of the NCCN Guidelines for Adolescent and Young Adult Oncology from Version 2.2017 include:

[AYAO-7](#)

• Evaluation:

- ▶ Added: "Communication preferences and potential barriers (eg, literacy and language considerations as well as preferred learning methods)."
- ▶ Added: "Adjustment to illness."
- ▶ Added "Provide opportunity for patient to share his/her cancer story."
- ▶ Modified: "Evaluate for *current and past* psychiatric symptoms, *including anxiety and depression*."
- ▶ Added: "Relational identity."

[AYAO-8](#)

• Evaluation:

- ▶ Modified: "Tobacco, alcohol, *cannabis*, or *other* substance use/abuse."
- ▶ Modified: "Exercise needs, *hobbies*, and *recreational activities*."
- ▶ Added: "*Sleep patterns*."
- ▶ Added: "*Use of both integrative therapies and complementary and alternative medicine (CAM)*."

• Supportive Care Services/Interventions:

- ▶ Added: "Provide education about the impact of early cannabis use on cognitive development and mental health."
- ▶ Added: "If AYA chooses to continue use, provide education on risks and benefits of varying methods of ingestion and dosing."
- ▶ Modified: "Provide education about *the impact of treatment on sexual health including safe sexual practices in light of risk of infection, risk for bleeding, prevention of pregnancy, and sexually transmitted diseases*."
- ▶ Modified: "*Provide education about potential diet/nutritional changes associated with cancer treatment and possible interventions*."
- ▶ Added: "Refer to reputable providers of integrative therapies and CAM services."

[AYAO-9](#)

• Evaluation:

- Family status, added "Interaction and relationship with sibling(s)"
 - ▶ Added: "Sexual orientation."
 - ▶ Added: "Consider role of cultural and/or family values."
- Supportive care services/interventions:
 - ▶ Added: "Social networking opportunities."
 - ▶ Modified: "~~Health care professionals should~~ *Communicate directly* with individual patients."
 - ▶ Modified: "~~Provide age-appropriate~~ *developmentally appropriate* information about their cancer, treatment options, and potential side effects."
 - ▶ Added: "Encourage completion of a medical power of attorney when appropriate."

[AYAO-10](#)

• Evaluation:

- ▶ Added: "Health insurance marketplace."
- ▶ Modified: "~~Loss~~ *Stability* of housing and *basic household socioeconomic needs*."
- Supportive care services/interventions:
 - ▶ Added: "Provide information on obtaining financial assistance with fertility needs. Local and institutional grants may be available."
 - ▶ Added: "Refer for career counseling and/or education support as indicated."

[AYAO-11](#)

- Added: "*Encourage relationship with primary health care provider for routine health issues*."
- Modified: "HPV vaccine is recommended for males *and females* 9–26 years of age except in high-risk groups."
- Abdominal or pelvic radiation, added: "Assess for bowel *incontinence*."
- Cisplatin/carboplatin, added: "*Screening for peripheral neuropathy*."

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

Updates in Version 1.2018 of the NCCN Guidelines for Adolescent and Young Adult Oncology from Version 2.2017 include:

AYAO-A

- Bone and Soft Tissue Sarcomas:

- ▶ Ewings sarcoma, added:

- ◊ Inferior outcomes for patients >18 years of age.
- ◊ Patients >18 years of age often have increased difficulty tolerating dose-dense treatments

- ▶ Modified: "Melanocytic tumors of uncertain malignant potential (MELTUMP) are more frequently seen in younger patients, and when suspected, ~~referral to~~ *consultation with* a pathologist with expertise in atypical melanocytic lesions is recommended."

AYAO-B (2 of 3)

- Breast cancer screening:

- ▶ Added: "Chest radiation between 10 and 20 Gy, participate in shared decision-making about screening."

AYAO-B (3 of 3)

- Hemorrhagic cystitis/bladder fibrosis and Bladder cancer:

- ▶ Changed: "Screening recommendation: urinalysis, yearly" to "Screening of pertinent urinary tract symptoms is recommended."

- Removed: "Complete blood count (CBC)/differential yearly, up to 10 years after exposure"

- Added: "Complete blood count (CBC) and bone marrow exam as clinically indicated based on symptoms."

AYAO-C

- Removed "Four main palliative care principles for the AYA population."

- Modified first paragraph "Palliative care focuses on symptom control, reduction of physical suffering or discomfort, and optimizing quality of life at any stage of a life-threatening disease. (See NCCN Guidelines for Palliative Care) Referral to palliative care is appropriate when patients are being treated with curative intent and can be initiated at the time of initial diagnosis. A palliative care team is multidisciplinary, with resources and expertise to address the psychosocial, emotional, and physical challenges relevant to the patient. Strategies to support a patient, particularly in the AYA population, must be individualized in context of the family dynamic, including maturity of the patient and level of independence (both desired and actual)."

- Added "Palliation of symptoms is an important aspect of end-of-life care."

- Removed references: "D'Agostino NM, Penney A, Zebrack B. Providing developmentally appropriate psychosocial care to adolescent and young adult cancer survivors. Cancer 2011;117:2329-2334" and "Zebrack BJ. Psychological, social, and behavioral issues for young adults with cancer. Cancer 2011;117:2289-2294."

AYAO-D

- Added: "Teen Cancer America <https://www.teencanceramerica.org/> Not-for-profit organization aiming to educate and support medical institutions and healthcare professionals in the development of specialized AYA cancer care units"

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

DEFINITION OF THE ADOLESCENT AND YOUNG ADULT ONCOLOGY POPULATION

The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database defines the Adolescent and Young Adult (AYA) Oncology patient as the one diagnosed at 15–29 years of age.^a NCI's AYA Oncology Progress Review Group defines AYA as a patient diagnosed at 15–39 years of age.^b In the NCCN Guidelines, AYA will be defined as patients 15–39 years of age at the time of initial cancer diagnosis.

PURPOSE OF THE NCCN GUIDELINES FOR AYA ONCOLOGY

Adolescents and young adult patients with cancer have a number of unique psychosocial concerns that have been identified by panels of experts, including (although not limited to) fertility preservation, parenting, schooling, employment attainment, and retention. The relative importance of these issues understandably varies markedly across the broad age range defined. These issues should be considered as part of the overall therapeutic plan for the patient. Specific recommendations are highlighted in the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology. Many centers have established AYA centers to accommodate the specific needs of patients with cancer in this age group. Consideration should be given to referring such patients to one of these AYA centers of excellence if feasible.

- These guidelines have been developed as supportive care guidelines and not as treatment guidelines. The purpose of the guidelines is to increase awareness of unique issues in AYA oncology, identify issues, and recommend interventions unique to the AYA population. In addition, these guidelines will identify resources available to the AYA population, include appropriate tabular materials, and make recommendations per patient management.
- AYA patients diagnosed with cancer should be recognized as distinct age groups that have unique medical and psychosocial needs. The frequency of distribution of cancer types is dramatically different across the age spectrum of the AYA population.^c
- The distinct biology of disease as well as other age-related issues in the AYA population (fertility, long-term side effects, insurance/financial issues, transportation to clinic appointments, child care, psychosocial support, and adherence to therapy) should be considered in the treatment decision-making process.
- The goal of the NCCN Guidelines for AYA Oncology is to identify issues specific to the AYA population; recommend interventions unique to the AYA population; educate physicians regarding the prevalence of cancer in AYAs; discuss long-term consequences; explain special considerations related to cancer management in AYA patients that aim to improve treatment tolerance, compliance, and clinical outcomes; and promote participation in clinical trials.
- Participation in clinical trials as well as enrollment on tumor banking and biologic protocols should be strongly encouraged in the AYA population.

^aBleyer A, O'Leary M, Barr R, Ries L. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767 2006.

^bClosing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer Report of the Adolescent and Young Adult Oncology Progress Review Group. 2006. http://planning.cancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf


^c[See Age-Specific SEER Incidences of Cancer by Age Group and Sex in the AYA Population \(2008–2012\) \(AYAO-4\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



SCREENING, ASSESSMENT, AND EVALUATION



^cSee Age-Specific SEER Incidences of Cancer by Age Group and Sex in the AYA Population (2008–2012) (AYAO-4).

^dSee Definition of AYA Population (AYAO-1).

^eThese centers provide a multidisciplinary approach involving a team of providers with expertise in cancer treatment and management of specific mental health and developmental issues such as fertility, education, career development, employment, family planning, pregnancy, sexually transmitted diseases, smoking, and substance abuse.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

COMPREHENSIVE ASSESSMENT

- Provide age-appropriate information related to cancer
[See Online Resources for AYA Patients and Survivors \(AYAO-D\)](#)
- All women of child-bearing potential must receive a pregnancy test prior to initiating therapy
- Discuss contraception prior to initiating therapy
- Discuss risks of infertility due to cancer and its therapy, as well as options for fertility preservation
[See Fertility/Endocrine Considerations \(AYAO-6\)](#)
- Psychosocial assessment
 - See Psychosocial/Behavioral Considerations
 - ◊ [Individual \(AYAO-7 and AYAO-8\)](#)
 - ◊ [Relationships \(AYAO-9\)](#)
 - ◊ [Socioeconomic Issues \(AYAO-10\)](#)
 - [See NCCN Guidelines for Distress Management](#)
- Recommend referral for genetic and familial risk assessment/counseling as appropriate based on clinical/family history and histologic diagnosis
 - Risk factors for breast cancer
 - ◊ Germline mutations of *BRCA1*, *BRCA2*, *TP53* (Li-Fraumeni syndrome), or *PTEN* (Cowden syndrome)
[See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian](#)
 - ◊ Chest irradiation
 - Risk factors for colon cancer
 - ◊ Mutations in *MMR* genes [hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome)] or *APC* genes [familial adenomatous polyposis (FAP)]
[See NCCN Guidelines for Colorectal Cancer Screening](#)
 - Risk factors for sarcomas [See NCCN Guidelines for Soft Tissue Sarcoma](#)
 - ◊ Li-Fraumeni syndrome
 - ◊ Germline mutations in the retinoblastoma (*Rb*) gene or succinate dehydrogenase (*SDH*) gene. Testing for germline mutations in the SDH subunit genes should be considered for AYAs with wild-type gastrointestinal stromal tumors (GIST) (lacking KIT or PDGFRA mutations) or paragangliomas
 - ◊ FAP-associated desmoid tumors (aggressive fibromatosis) [See NCCN Guidelines for Colorectal Cancer Screening](#)
 - ◊ Germline mutations in neurofibromatosis-1 (*NF-1*) gene are associated with malignant peripheral nerve sheath tumor (MPNST)
 - Risk Factors for Multiple Endocrine Neoplasms (MEN)
 - ◊ [See NCCN Guidelines for Neuroendocrine Tumors](#)

Treatment-related
issues

→ [See AYAO-5](#)

Fertility/
endocrine

→ [See Fertility/
Endocrine
Considerations
\(AYAO-6\)](#)

Adherence
to treatment

→ [See
Psychosocial/
Behavioral
Considerations
\(AYAO-7 and
AYAO-8\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

Age-Specific SEER Incidences of Cancer by Age Group and Sex in the AYA Population (2010–2014)^{f,9}

Cancer type	Ages 15–19		Ages 20–24		Ages 25–29		Ages 30–34		Ages 35–39	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Bone sarcomas	1.9	1.2	1.2	0.8	0.8	0.8	0.8	0.5	0.8	0.8
Carcinoma of breast				1.4		8.9		26.9	0.2	60.1
CNS cancers	2.4	2.1	2.3	2.0	3.2	2.6	3.9	2.8	4.3	2.9
Carcinoma of cervix and uterus		0.1		1.4		6.4		13.9		20.7
Carcinoma of colon and rectum	0.4	0.5	1.2	1.1	2.7	2.6	5.4	5.3	10.1	9.5
Carcinoma of head and neck	0.5	0.5	0.8	0.7	1.1	1.0	2.0	1.8	3.9	2.8
Carcinoma of respiratory tract		0.1	0.3	0.3	0.5	0.6	1.0	1.1	2.6	2.5
Carcinoma of kidney	0.2	0.2	0.4	0.4	1.2	1.2	3.2	2.3	6.4	4.0
Germ cell neoplasms	4.5	1.2	11.0	1.2	15.4	1.1	14.3	0.9	11.5	0.7
Leukemias	3.8	2.6	3.1	2.3	3.3	2.5	3.9	3.1	5.0	3.9
Lymphomas										
HL	3.1	3.0	4.0	4.3	3.9	4.0	3.7	3.2	3.0	2.6
NHL	2.5	1.2	3.1	2.1	3.8	2.8	5.5	3.9	8.0	5.8
Melanoma	0.9	1.1	2.0	5.0	4.3	8.7	6.9	12.5	10.2	14.5
Soft tissue sarcomas	1.4	1.3	2.2	1.6	3.2	2.1	4.6	2.8	4.5	3.5
Thyroid carcinoma	0.9	4.9	1.9	9.9	3.2	17.6	5.4	25.2	7.5	31.8

^fThese are incidence rates per 100,000.

⁹Data from Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER website, April 2017.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

TREATMENT-RELATED ISSUES

- Dose schedules** →
- Selected AYA patients may tolerate more intensive therapies than older patients
 - Dose intensity and dose density are associated with improved outcomes^h
 - [See NCCN Guidelines for Myeloid Growth Factors](#) for growth factor support
 - Dose reductions are often based upon avoiding severe, irreversible organ damage
 - Assume that the patient population has a significant long-term survival and that significant end-organ damage may compromise long-term function and quality of life
 - Monitoring of cumulative dosing and schedule for certain medications associated with irreversible organ damage and fertility issues may be essential when certain lifetime exposure is encountered. [See AYAO-11 for specific agents.](#)
 - Maximum cumulative dosing parameters are often established for a patient to reduce the risk of significant irreversible damage
- Toxicities** →
- Reversible toxicities do not necessarily warrant dose reductions.
See NCCN Guidelines for Supportive Care for the management of treatment-related toxicities, including:
 - [See NCCN Guidelines for Adult Cancer Pain](#)
 - [See NCCN Guidelines for Antiemesis](#)
 - [See NCCN Guidelines for Cancer- and Chemotherapy-Induced Anemia](#)
 - [See NCCN Guidelines for Cancer-Related Fatigue](#)
 - [See NCCN Guidelines for Palliative Care](#)
 - [See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#)
 - Screening is recommended for the following treatment-related toxicities:
 - Cardiac toxicity - Regular echocardiograms. A baseline electrocardiogram (ECG) is only recommended after completion of treatment - [See Screening Recommendations \(AYAO-B\)](#). Recommend adding cardioprotectant (eg, dexrazoxane) for patients receiving an anthracycline.
 - Renal toxicity - Regular glomerular filtration rate (GFR) calculations to monitor renal toxicity associated with cisplatin- and ifosfamide-based chemotherapy
 - Neurotoxicity - Regular audiogram to monitor hearing loss associated with cisplatin- or carboplatin-based chemotherapy
 - Routine endocrine, ophthalmology, and dental evaluations for patients with selected radiation exposure and/or total body irradiation (TBI) for stem cell transplant
 - Infertility - See Screening Recommendations ([AYAO-B, 3 of 3](#))

^hWomer RB, West DC, Krailo MD, et al. J Clin Oncol 2012;30:4148-4154. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Leukemia 2015;29:526-534. Gerber NK, Wexler LH, Singer S, et al. Int J Radiat Oncol Biol Phys 2013;86:58-63.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

FERTILITY/ENDOCRINE CONSIDERATIONS

- Fertility preservation as well as sexual health and function should be an essential part in the management of AYAs with cancer who are at any risk for infertility due to cancer treatmentsⁱ
- Discuss risks for infertility due to cancer and its therapy (especially for high-risk therapies such as alkylating agents or gonadal irradiation), fertility preservation, and contraception prior to the start of therapy^j
 - Men are at risk for azoospermia following therapy, which may or may not resolve over time
 - Women are at risk for premature ovarian failure following therapy

- Initiate referral for fertility preservation clinics within 24 hours for all patients who choose the option of fertility preservation
- Refer to a mental health professional to assist with complex decision making if needed.
[See Psychosocial/Behavioral Considerations \(AYAO-7 and AYAO-8\)](#)

Males

- Discuss the option of sperm banking
- Suggest a local sperm bank, or available online sperm banking kit
- Consider follow-up with fertility specialist post-treatment

Females

- Discuss the option of embryo or oocyte cryopreservation or ovarian tissue cryopreservation (if available)
 - Initiate if provider deems that therapy can be delayed long enough for a cycle of oocyte stimulation (for low- and intermediate-risk Hodgkin's lymphoma, low-grade sarcomas, and breast cancer)
- Consider follow-up with fertility specialist post-treatment
- Oophoropexy
 - Ovaries may be surgically moved away from the planned radiation field, either during cancer surgery or in a separate procedure
- Menstrual suppression
 - Medroxyprogesterone, oral contraceptives, or gonadotropin-releasing hormone (GnRH) agonists may be used in protocols that are predicted to cause prolonged thrombocytopenia and present a risk for menorrhagia
 - It is controversial whether menstrual suppression would protect the ovaries, but some data suggest that menstrual suppression with GnRH agonists may protect ovaries in young women with breast cancer before the initiation of chemotherapy.^k

ⁱLevine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831-4841.

^jThe impact of cancer therapy on fertility is related to the age of the patient at the time of treatment and is dependent on the duration, dose intensity, and type of treatment. [See NCCN Guidelines for Breast Cancer](#) for the management of women with breast cancer during pregnancy.

^kMoore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-932.

Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 2016;34:2568-2574.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

PSYCHOSOCIAL CONSIDERATIONS: INDIVIDUAL EVALUATION

- **Psychosocial factors:**
 - **Cognitive function**
 - ◊ Developmental stage
 - **Communication preferences and potential barriers (eg, literacy and language considerations as well as preferred learning methods)**
 - **Adjustment to illness**
 - ◊ Provide opportunity for patient to share his/her cancer story.
 - **(See [NCCN Guidelines for Distress Management](#))**
 - **Evaluate for current and past psychiatric symptoms, including anxiety and depression**
 - **Involvement/interruption of school/work**
 - **Living status**
 - ◊ Alone
 - ◊ Spouse/partner
 - ◊ Parents
 - ◊ Children
 - **Impact of cancer on identity**
 - ◊ Personal values
 - ◊ Self-esteem
 - ◊ Relational identity
 - ◊ Body image and physical changes
 - ◊ Strengths/resilience
 - ◊ Future goals

SUPPORTIVE CARE SERVICES/INTERVENTIONS

- Refer AYA patients with cognitive dysfunction or other psychiatric symptoms (eg, depression, anxiety) to a mental health provider and community-based resources serving AYA patients.
- Offer psychosocial support and counseling to help alleviate distress. ([See NCCN Guidelines for Distress Management](#))
- Consider flexible treatment dates, consultation times, and procedures (evenings/weekends).
- For all AYA patients, provide counseling around decision-making regarding the risks of treatment-related infertility and discuss options for fertility preservation prior to the start of therapy. [See Fertility/Endocrine Considerations \(AYAO-6\)](#)

Individual: Behavioral factors → [See AYAO-8](#)

Relationships → [See AYAO-9](#)

Socioeconomic issues → [See AYAO-10](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

BEHAVIORAL CONSIDERATIONS: INDIVIDUAL EVALUATION

- Behavioral factors:
 - ▶ Adherence to therapy
 - ▶ Tobacco, alcohol, cannabis, or other substance use/abuse
 - ▶ Sexual behavior/risks/concerns
 - ▶ Assess nutritional requirements and potential deficits based on age
 - ▶ Exercise needs, hobbies, and recreational activities
 - ▶ Sleep patterns
- Use of both integrative therapies and complementary and alternative medicine (CAM)
- Existential/spiritual issues

SUPPORTIVE CARE SERVICES/INTERVENTIONS

- Adherence to therapy
 - ▶ Educate about the expectations of treatment and explain the patient's responsibility to adhere to therapy.
 - ▶ Provide education and/or guidance about each medication prior to the start of treatment and every time there is a change in treatment.
 - ▶ Review list of medications and their dose, purpose, and adverse effects.
 - ▶ Simplify dosing schedule and change timing and frequency of medication or method of administration, when medically possible, to fit into AYAs' lifestyle and normal activities.
 - ▶ Provide access to systematic and standardized symptom management for side effects related to cancer treatment. [See NCCN Guidelines for Supportive Care](#)
- Refer to smoking cessation program if needed. [See NCCN Guidelines for Smoking Cessation](#)
- Provide education about the impact of early cannabis use on cognitive development and mental health.
 - ▶ If AYA chooses to continue use, provide education on risks and benefits of varying methods of ingestion and dosing.
- Refer patients with signs, symptoms, and a history of substance abuse or addiction to a risk reduction or substance abuse management program.
- Provide education about the impact of treatment on sexual health including safe sexual practices in light of risk of infection, risk for bleeding, prevention of pregnancy, and sexually transmitted diseases. See WHO recommendations in the [Discussion section](#).
- Provide education about potential diet/nutritional changes associated with cancer treatment and possible interventions. Refer to registered dietitian-certified specialist in oncology (RD-CSO).
- Refer to reputable providers of integrative therapies and CAM services.
- Refer patients experiencing challenges with their faith or belief in a just or fair world to faith-based resources or activities (eg, church youth groups, mentors). If necessary, refer to a chaplain or pastoral counselor.

Relationships —————→ [See AYA0-9](#)

Socioeconomic issues —————→ [See AYA0-10](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

PSYCHOSOCIAL/BEHAVIORAL CONSIDERATIONS: RELATIONSHIPS

EVALUATION

- Family status
 - Interaction and relationship with parents
 - Interaction and relationship with spouse/partner
 - Interaction and relationship with sibling(s)
 - Patient with young children
- Peer relationships
- Sexual orientation
- Participation in community and social activities (eg, religious organizations, clubs, athletics/recreation, music, youth groups)
- Communications with health care professionals
 - Decision-making preferences: family, friend, clinical care team, and/or self
 - Information and communication preferences (eg, visual, auditory)
 - Consider role of cultural and/or family values

SUPPORTIVE CARE SERVICES/INTERVENTIONS

- Promote communication between AYA patients and family members:
 - Parents
 - Spouse/partners
 - Siblings
- Provide family members and partners with information about psychosocial support and behavioral services.
 - Increase awareness of the possible psychosocial issues associated with cancer diagnosis in AYAs, so that family members and partners may continue to support the patient.
- Consider the following family-based intervention models from pediatric studies, which may have utility for AYAs:
 - Parent support groups
 - AYA support groups
 - Social and recreational programs
 - Psychoeducational programs
- Provide information about peer support to assist AYAs establishing and maintaining relationships with their peers as well as with other AYAs with cancer. [See Online Resources for AYA Patients and Survivors \(AYAO-D\)](#)
 - Face-to-face meetings
 - Camp and retreat programs
 - Online support groups
 - Social networking opportunities
- Create flexible visiting hours and an environment that will encourage peers to visit AYA patients.
- Communicate directly with individual patients.
 - Ask for permission to share information with family members.
 - Provide developmentally appropriate information about their cancer, treatment options, and potential side effects. [See Online Resources for AYA Patients and Survivors \(AYAO-D\)](#)
- Encourage completion of a medical power of attorney when appropriate.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

PSYCHOSOCIAL/BEHAVIORAL CONSIDERATIONS: SOCIOECONOMIC ISSUES

EVALUATION

SUPPORTIVE CARE SERVICES/INTERVENTIONS

- Insurance availability and security
 - ▶ Employer-provided
 - ▶ Parent's insurance
 - ▶ Health insurance marketplace
- Assessment of risk for losing insurance
 - ▶ Loss of employment
 - ▶ Age out of parents' insurance
- Risk for financial loss or bankruptcy
- Child care
- Transportation
- Accommodation if traveling to receive treatment
- Stability of housing and basic household socioeconomic needs



- Link qualified AYA patients to Medicaid, social security, and/or disability insurance.
- Educate AYA patients about benefits they may qualify for, such as short- or long-term disability, state disability benefits, and public assistance.
- Provide information on obtaining financial assistance with fertility needs. Local and institutional grants may be available.
- Refer for career counseling and/or education support as indicated.
- Direct AYA patients to legal resources/advocates for understanding health insurance coverage.
- Identify resources for respite care for AYA patients with young children.
- Refer to transportation assistance programs (eg, van ride programs, voucher programs).
- Provide AYAs with a list of recommended and reliable online sources to access information related to their cancer. [See Online Resources for AYA Patients and Survivors \(AYAO-D\)](#)
- Financial assistance for AYA cancer survivors needs to be integrated into survivorship plans.
- AYAs with cancer need long-term follow-up care for monitoring and treatment of late effects long after completion of treatment.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

SURVIVORSHIP

AYA cancer survivor^l

- Develop a “Cancer Treatment Summary and Survivorship Care Plan” [See NCCN Guidelines for Survivorship](#)
- Provide a periodic evaluation focusing on history, physical examination, and screening based on treatment exposures and risk for treatment-related late effects
- Encourage relationship with primary health care provider for routine health issues.
- Recommend vaccinations:
 - HPV vaccine is recommended for males and females 9–26 years of age except in high-risk groups^m
 - Annual influenza vaccine
- Counsel regarding lifestyle practices and methods to reduce risk (eg, avoiding smoking, increasing level of physical activity)
- Advocate for appropriate health care coverage
- Recommend a dental exam and cleaning every 6 mo for patients who received chemotherapy and/or radiation therapy

SELECTED EXPOSURES

Cranial or
craniospinal
radiation

Chest radiation

Abdominal or
pelvic radiation

Alkylating agents

Anthracyclines

Bleomycin

Cisplatin/
carboplatin

Epipodophyllotoxins

SCREENING RECOMMENDATIONS

[See Screening Recommendations \(AYAO-B\)](#)

- Neuroendocrine axis screening
- Neuropsychological evaluation

- Females: see breast cancer screening
- Thyroid screening
- Cardiovascular risk assessment and screening
- Screening for cardiomyopathy
- Screening for valvular heart disease
- Pulmonary screening

- Colorectal cancer screening
- Assessment of gonadal function
- Assess for bowel incontinence
- Screening for kidney or bladder disease

- Screening for kidney or bladder disease
- Assessment of gonadal function
- Screening for treatment-related AML (t-AML) or myelodysplasia
- Pulmonary screening (for selected agents)

- Screening for cardiomyopathy
- Screening for t-AML or myelodysplasia

- Pulmonary function screening

- Cardiovascular risk assessment
- Screening for kidney and/or bladder disease
- Audiological evaluation
- Screening for t-AML or myelodysplasia
- Screening for peripheral neuropathy

- Screening for t-AML or myelodysplasia

^lAn individual is considered a cancer survivor from the time of diagnosis, through the balance of his or her life. Family members, friends, and caregivers are also impacted. Adapted with permission from the National Coalition for Cancer Survivorship as shown in the National Cancer Institute’s About Cancer Survivorship Research: Survivorship Definitions webpage.

^mFurther details are here: <http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

DISEASE-SPECIFIC ISSUES RELATED TO AGE

Acute Lymphoblastic Leukemia (ALL)

- [See NCCN Guidelines for ALL](#)

Bone and Soft Tissue Sarcomas

- [See NCCN Guidelines for Bone Cancer](#) and [NCCN Guidelines for Soft Tissue Sarcoma](#)
- Rhabdomyosarcoma
 - ▶ Uncommon outside of the pediatric population; should be referred to an institution with experience in the management of rhabdomyosarcoma
- Ewing's sarcoma
 - ▶ Inferior outcomes for patients >18 years of age.
 - ▶ Patients >18 years of age often have increased difficulty tolerating dose-dense treatments

Colorectal Cancer

- Higher incidence of mucinous histology
- More often right-sided
- Higher incidence of signet ring cells and microsatellite instability (MSI)
- More advanced stage at diagnosis
- Lower incidence of *KRAS* mutations
- Decreased incidence of chromosomal instability
- Consider mismatch repair gene deficiency in these patients
- Increased risk for additional malignancies

Melanoma

- Melanocytic tumors of uncertain malignant potential (MELTUMP) are more frequently seen in younger patients, and when suspected, consultation with a pathologist with expertise in atypical melanocytic lesions is recommended.
- Conventional melanomas in AYA have a similar behavior and a similar genomic signature when compared to melanomas in older patients. These patients should be offered similar treatment options. [See NCCN Guidelines for Melanoma](#).

Management of Cancer During Pregnancy ([See Discussion](#))

- AYA women diagnosed with cancer during pregnancy should be managed by a multidisciplinary team involving medical, surgical, and radiation oncologists; gynecologic oncologists; obstetricians; and perinatologists as appropriate.
- Selection of an appropriate treatment plan is dependent on individual tumor biology, tumor stage, and most importantly the gestational stage of the fetus.
- Referral to tertiary cancer centers with expertise in diagnosis and treatment of cancer during pregnancy, maternal-fetal medicine, and knowledge of the physiological changes that occur during pregnancy should be strongly encouraged.
- Chemotherapy should be avoided during the first trimester because of greater risk of teratogenic effects and intrauterine fetal death.
- RT is contraindicated during pregnancy. In very rare instances when RT is necessary, it should be delivered in low therapeutic doses with adequate uterine shielding to minimize fetal exposure.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

SCREENING RECOMMENDATIONS FOR AYA SURVIVORS

The recommendations listed here include general principles; for more detail refer to the [Children's Oncology Group \(COG\)](#).

Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers

- The recommendations represent only key aspects; for more detail, refer to the website, [survivorshipguidelines.org](#).
- See also [NCCN Guidelines for Survivorship](#)
- The COG Guidelines are based on exposures used in the treatment for pediatric cancer. As such, the recommendations are applicable to many survivors of cancers that span across adolescence and young adulthood, such as acute leukemias, Hodgkin's and non-Hodgkin's lymphomas, medulloblastomas, and sarcomas. In addition, since the treatment exposures for some young adult cancers, such as male germ cell tumors, are similar to pediatric cancer treatments (eg, cisplatin, bleomycin, abdominal irradiation), the recommendations may be applicable. In contrast, the COG recommendations are generally not applicable to survivors of typical adult carcinomas occurring during young adulthood, such as breast, colorectal, and ovarian cancers.
- The risk for many late effects may be influenced by family history, lifestyle behaviors, and comorbid health conditions. The following recommendations are based on the treatment exposure; timing and intensity of screening may be adapted based on additional risk factors.
- Most survivors will have multiple treatment exposures, and therefore may have multiple screening needs.

Neuroendocrine Axis Screening (selected outcomes)

- Growth hormone deficiency
 - ▶ High-risk population: radiation dose to hypothalamic-pituitary-adrenal (HPA) axis >18 Gy

- ▶ Screening recommendation: height, weight, and body mass index every 6 months until growth is completed then yearly. Note: most AYA patients will have attained (or nearly attained) final height; the significance and management of growth hormone status among survivors who attained their final height is controversial.
- ▶ Consider endocrine consultation for height below the third percentile on the growth curve, or drop of less than second percentile rankings on the growth chart.
- Central hypothyroidism
 - ▶ High-risk population: total radiation dose to HPA axis >40 Gy
 - ▶ Screening recommendation: thyroid-stimulating hormone (TSH) and free T4, yearly
- Gonadotropin deficiency
 - ▶ High-risk population: total radiation dose to HPA axis >40 Gy
 - ▶ Screening recommendation: follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (males) and FSH, LH, and estradiol (females) as clinically indicated; semen analysis (males) as requested by patient or for evaluation of fertility
- Central adrenal insufficiency
 - ▶ High-risk population: total radiation dose to HPA axis >40 Gy
 - ▶ Screening recommendation: 8:00 AM serum cortisol, yearly for at least 15 years after treatment and as clinically indicated

Neuropsychological Evaluation

- Severe neurocognitive deficits are uncommon in survivors of AYA cancer, including CNS tumors. However, subtle deficits in executive function, sustained attention, memory, and processing speed may occur with higher-dose cranial radiation (>18 Gy)
- Screening recommendation: In patients with evidence of impaired educational or vocational progress, formal neuropsychological evaluation is recommended

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

SCREENING RECOMMENDATIONS FOR AYA SURVIVORS

Breast Cancer Screening (females)

- High-risk population: chest radiation >20 Gy prior to the age of 30 years
 - ▶ Chest radiation between 10 and 20 Gy, participate in shared decision-making about screening
- Screening recommendation: breast MRI and mammogram yearly, starting at age 25 or 8 years after radiation, whichever occurs last

Cardiovascular Risk Assessment and Screening

- High-risk populations: TBI, mediastinal/chest radiation >20 Gy
- Screening recommendation: measure blood pressure and body mass index yearly; fasting glucose, lipid profile every 2 years
- Screening for ischemic coronary artery disease remains controversial; consider cardiology consultation (5–10 years after radiation) in patients who received >40 Gy chest radiation

Screening for Cardiomyopathy/Asymptomatic Heart Failure

- High-risk population: cumulative anthracycline dose >300 mg/m²; chest radiation >30 Gy; combination of anthracycline and chest radiation
- Screening recommendation: echocardiogram (or MUGA scan) every 1–2 years (Note: Frequency of testing is dependent on both age at time of exposure and dose of exposure. The frequency of testing has not been established for breast cancer survivors treated with lower cumulative doses of anthracyclines.) A baseline ECG is only recommended after completion of treatment

Screening for Valvular Heart Disease

- High-risk population: chest radiation >30 Gy
- Screening recommendation: echocardiogram every 1–2 years

Pulmonary Screening

- High-risk population: chest radiation >15 Gy (or radiation to large volume of lung), TBI (>6 Gy in single fraction or >12 Gy fractionated), bleomycin >400 U/m², combination of chest radiation and bleomycin, and selected alkylating agents (busulfan >500 mg, carmustine >600 mg/m²)
- Screening recommendation: pulmonary function tests (including diffusion lung capacity for carbon monoxide [DLCO] and spirometry) as a post-therapy baseline and then as clinically indicated in patients with abnormal results or progressive pulmonary dysfunction

Thyroid Screening

- Thyroid disorders: hypothyroidism (very common), thyroid cancer (common), and hyperthyroidism (uncommon)
- High-risk population: radiation field includes the thyroid gland (see neuroendocrine axis screening for high-dose cranial radiation)
- Screening recommendation: TSH and thyroid/neck exam, yearly

Colorectal Cancer Screening

- High-risk population: abdominal or pelvic radiation >30 Gy
- Screening recommendation: colonoscopy starting at age 35 or 10 years after radiation, whichever occurs last

Screening for Kidney and/or Bladder Disease

- Renal insufficiency and secondary renal/renovascular hypertension
 - ▶ High-risk population: radiation >10 Gy, combination of radiation with nephrotoxic agents (eg, cisplatin, ifosfamide, aminoglycosides, amphotericin, immunosuppressants)
 - ▶ Screening recommendation: post-therapy baseline blood urea nitrogen (BUN), creatinine, Na, K, Cl, CO₂, Ca, Mg, and PO₄; repeat as clinically indicated; measure blood pressure yearly; and measure urinalysis yearly

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

SCREENING RECOMMENDATIONS FOR AYA SURVIVORS

- Hemorrhagic cystitis/bladder fibrosis
 - ▶ High-risk population: cyclophosphamide >3 gm/m², pelvic radiation >30 Gy
 - ▶ Screening of pertinent urinary tract symptoms is recommended
- Bladder cancer
 - ▶ High-risk population: cyclophosphamide combined with pelvic radiation
 - ▶ Screening of pertinent urinary tract symptoms is recommended

Assessment for Gonadal Function

- Males
 - ▶ Infertility
 - ◊ High-risk population: moderate- to high-dose alkylating agent chemotherapy (eg, MOPP >3 cycles, busulfan >600 mg/m², cyclophosphamide cumulative dose >7.5 gm/m² or as conditioning for hematopoietic cell transplant, ifosfamide cumulative dose >60 gm/m²), TBI, testicular irradiation >2 Gy, and any alkylator combined with testicular irradiation or TBI
 - ◊ Screening recommendation: semen analysis as requested by patient or for evaluation of infertility; periodic evaluation over time is recommended as resumption of spermatogenesis can occur up to 10 years post therapy
 - ▶ Leydig cell dysfunction
 - ◊ High-risk population: testicular irradiation >20 Gy
 - ◊ Screening recommendation: testosterone as clinically indicated in patients with clinical signs and symptoms of testosterone deficiency

- Females
 - ▶ Infertility (acute ovarian failure or premature menopause)
 - ◊ High-risk population: moderate- to high-dose alkylating agent chemotherapy (eg, MOPP >3 cycles, busulfan >600 mg/m², cyclophosphamide cumulative dose >7.5 gm/m² or as conditioning for hematopoietic cell transplant, ifosfamide cumulative dose >60 gm/m²), TBI, and abdominal and/or pelvic radiation
 - ◊ Screening recommendation: AMH (anti-mullerian hormone), FSH, and LH testing, estradiol as indicated in patients with irregular menses, primary or secondary amenorrhea, and/or clinical signs and symptoms of estrogen deficiency
 - ◊ Referral to gynecology, reproductive medicine, or endocrinology is recommended for post-pubertal survivors treated with potentially gonadotoxic chemotherapy and/or radiotherapy.

Screening for t-AML or Myelodysplasia

- High-risk populations: epipodophyllotoxins, alkylating agents, cisplatin, and/or anthracyclines
- Screening recommendation: CBC and bone marrow exam as clinically indicated based on symptoms.

Audiologic Evaluation

- High-risk population: cisplatin >360 mg/m², carboplatin conditioning for hematopoietic cell transplant, radiation involving the ear >30 Gy, and combination of cisplatin and cranial/ear radiation
- Screening recommendation: audiology testing as a post-therapy baseline and then as clinically indicated for signs and symptoms of hearing loss

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PALLIATIVE CARE and END-OF-LIFE CONSIDERATIONS

Palliative care focuses on symptom control, reduction of physical suffering or discomfort, and optimizing quality of life at any stage of a life-threatening disease. (See [NCCN Guidelines for Palliative Care](#)) Referral to palliative care is appropriate when patients are being treated with curative intent and can be initiated at the time of initial diagnosis.¹ A palliative care team is multidisciplinary, with resources and expertise to address the psychosocial, emotional, and physical challenges relevant to the patient.² Strategies to support a patient, particularly in the AYA population, must be individualized in context of the family dynamic, including maturity of the patient and level of independence (both desired and actual).

End-of-life considerations

- Palliation of symptoms is an important aspect of end-of-life care.
- It is imperative for health care professionals not to assume that AYA patients may be less inclined to discuss death and other end-of-life issues.²
- Discussion about end-of-life preferences should begin early in treatment, but details should be individualized according to the preferences of the AYA patient and family.³
- Many adolescents indicate a preference for dying at home, yet 80% die in hospitals.^{4,5}
- Physicians with experience in end-of-life care should facilitate discussion about issues such as nutrition/hydration, sedation treatment cessation, and place of death.²
- An advance care planning document is recommended for terminally ill AYA patients with metastatic cancer.^{3,6}
- Ongoing psychosocial support is extremely important during the transition to end-of-life care. For family and friends, grief from loss may begin before death.

¹Pritchard S, Cuvelier G, Harlos M, Barr R. Palliative care in adolescents and young adults with cancer. *Cancer* 2011;117:2323-2328.

²Wein S, Pery S, Zer A. Role of palliative care in adolescent and young adult oncology. *J Clin Oncol* 2010;28:4819-4824.

³Wiener L, Zadeh S, Wexler LH, Pao M. When silence is not golden: Engaging adolescents and young adults in discussions around end-of-life care choices. *Pediatric Blood & Cancer* 2013;60:715-718.

⁴Bell CJ, Skiles J, Pradhan K, Champion VL. End-of-life experiences in adolescents dying with cancer. *Support Care Cancer* 2010;18:827-835.

⁵Webb NM, Tucker D. Young adults' opinions about hospice and home death. *J Palliat Med* 2009;12:337-342.

⁶Wiener L, Ballard E, Brennan T, et al. How I wish to be remembered: the use of an advance care planning document in adolescent and young adult populations. *J Palliat Med* 2008;11:1309-1313.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

AYAO-C



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

ONLINE RESOURCES FOR AYA PATIENTS AND SURVIVORS - [See NCCN Guidelines for Patients: Caring for Adolescents and Young Adults](#)

General Information on Cancer in AYAs:

Teen Cancer America

<https://www.teencanceramerica.org/>

Not-for-profit organization aiming to educate and support medical institutions and health care professionals in the development of specialized AYA cancer care units

The 15-40 Connection

<http://www.15-40.org/>

Not-for-profit organization dedicated to motivating AYAs to take their health and medical care seriously, to take action when they notice changes in their health, and to be strong self-advocates when their instincts tell them something is wrong.

Planet Cancer

<http://myplanet.planetcancer.org/>

A community of peer support and advocacy for AYAs with cancer, designed to connect and empower AYAs and help them access support and resources.

Seventy K: Survival Up

<http://www.seventyk.org/>

Not-for-profit organization dedicated to improving cancer care by educating patients, families, and their health care providers about age-appropriate treatment and the unique needs of AYA cancer patients.

Stupid Cancer (The I'm Too Young for This! Cancer Foundation, i[2]y)

<http://stupidcancer.org>

The nation's largest online support community for AYAs affected by cancer.

Teens Living With Cancer

<http://www.13thirty.org>

National non-profit organization dedicated to helping teens and young adults live with cancer. This site contains teen-oriented resources designed to help teens cope with their disease and treatment and connect with other teens on the same ride.

Ulman Cancer Fund for Young Adults

<http://www.ulmanfund.org/>

Grassroots organization dedicated to supporting, educating, connecting, and empowering AYA cancer patients and survivors.

Cancer Diagnosis and Treatment:

American Cancer Society

<http://www.cancer.org/Treatment/UnderstandingYourDiagnosis/index>

Understanding Your Diagnosis

National Cancer Institute

<http://www.cancer.gov/about-cancer/managing-care/services/doctor-facility-fact-sheet>

How to Find a Doctor or Treatment Facility if You Have Cancer

National Center for Complementary and Integrative Health

<http://www.nccih.nih.gov/>

National Comprehensive Cancer Network

<http://www.nccn.org/patients/resources/diagnosis/staging.aspx>

Cancer Staging Guide

Navigate Cancer Foundation

<http://www.navigatecancerfoundation.org/>

This free, online program provides consultation services by experienced cancer nurses who can translate pathology reports, scans, and medical documents and help patients find a qualified doctor for a second opinion.

US National Institutes of Health

<http://www.clinicaltrials.gov/>

Registry and results database of publicly and privately supported clinical studies.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

ONLINE RESOURCES FOR AYA PATIENTS AND SURVIVORS - [See NCCN Guidelines for Patients: Caring for Adolescents and Young Adults](#)

Fertility Issues:

American Society of Clinical Oncology (ASCO)

<http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/fertility-preservation>

What to Know: ASCO's Guideline on Fertility Preservation

Fertile Hope

<http://www.livestrong.org/we-can-help/fertility-services/risks/>

Fertile Hope is a LIVESTRONG initiative dedicated to providing reproductive information, support, and hope to cancer patients and survivors whose medical treatments present the risk of infertility.

Hope for Two...The Pregnant with Cancer Network

<http://www.hopefortwo.org/>

Free support for women diagnosed with cancer while pregnant

LiveStrong

<https://www.livestrong.org/we-can-help/fertility-services>

MyOncofertility.org

<http://myoncofertility.org/>

Patient education resource provided by the Oncofertility Consortium.

The Oncofertility Consortium

<http://oncofertility.northwestern.edu/>

Research group dedicated to exploring the relationships between health, disease, survivorship, and fertility preservation in young cancer patients. Site includes information on fertility options and a map of oncofertility centers across the United States.

Verna's Purse

<http://www.vernaspurse.org/>

Financial assistance program for those in need of fertility services

Managing Side Effects:

American Institute for Cancer Research Nutrition information:

<http://www.aicr.org/reduce-your-cancer-risk/diet/>

American Society for Clinical Oncology (ASCO) videos:

Body changes: <http://www.cancer.net/navigating-cancer-care/videos/young-adults-cancer/body-changes>

American Society of Clinical Oncology (ASCO) Moving Forward Video Series for Young Adults with Cancer:

Diet and exercise

<http://www.cancer.net/navigating-cancer-care/videos/young-adults-cancer/diet-and-exercise>

Managing pain

<http://www.cancer.net/navigating-cancer-care/videos/young-adults-cancer/managing-pain>

Look Good, Feel Better

<http://lookgoodfeelbetter.org> (for women)

<http://www.lookgoodfeelbetterformen.org/> (for men)

Program dedicated to improving the self-esteem and quality of life of people undergoing cancer treatment. Includes information on how to manage the appearance-related side effects of treatment.

National Cancer Institute

Coping with Cancer: Managing Physical Effects

<http://www.cancer.gov/cancertopics/coping/physicaleffects/>

Nutrition in Cancer Care

<http://www.cancer.gov/cancertopics/pdq/supportivecare/nutrition/Patient/page1/>

National Institute of Health (NIH) Sleep Hygiene Guide

<http://www.nhlbi.nih.gov/files/docs/public/sleep/healthysleepfs.pdf>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

ONLINE RESOURCES FOR AYA PATIENTS AND SURVIVORS - [See NCCN Guidelines for Patients: Caring for Adolescents and Young Adults](#)

Navigating Life (During and After Treatment):

American Society of Clinical Oncology (ASCO)

Family life changes: <http://www.cancer.net/coping-and-emotions/communicating-loved-ones/family-life>

American Cancer Society Road to Recovery Program

<http://www.cancer.org/treatment/supportprogramsservices/road-to-recovery> Provides free ground transportation to patients receiving treatment. Volunteers available based on zip code.

Cancer101

<http://www.cancer101.org/>

CANCER101 helps cancer patients and their families function as active partners in their care. The site offers tools such as the Cancer101 Planner that can help patients navigate their cancer journey.

Cancer and Careers

Empowers and educates people with cancer to thrive in the workplace, by providing expert advice, interactive tools, and educational events.

<http://www.cancerandcareers.org/en>

Cancer Care

<http://www.cancercare.org/>

Provides free professional support services to anyone affected by cancer. All services—including counseling and support groups, education, financial assistance, and practical help—are provided by professional oncology social workers and are completely free of charge.

"Cancer in Our Family" (American Cancer Society)

<http://acs.bookstore.ipgbook.com/cancer-in-our-family-products-9780944235959.php>

Guide that helps parents teach children about the diagnosis, treatment, potential recurrences of the illness, and terminal illness.

Cancer.Net

<http://www.cancer.net/survivorship/late-effects>

Late Effects

CaringBridge.org

<http://www.caringbridge.org/>

Online space where cancer patients and their friends and family can connect, share, and receive support—kind of like a personalized social network. Available 24/7 to anyone, anywhere at no cost.

Caregiver Action Network

<http://caregiveraction.org/>

Provides resources for family and caregivers, such as education and peer support.

Family Patient Online Patient Update Reports

<http://www.familypatient.com/>

Website that allows family members to post up-to-date information about the condition of their loved ones.

FinAid! The Smart Student Guide To Financial Aid

<http://www.finaid.org/scholarships/cancer.phtml>

Information about scholarships for cancer patients, cancer survivors, children of a cancer patient or survivor, students who lost a parent to cancer, and students pursuing careers in cancer treatment.

First Descents

<http://firstdescents.org/>

Provides free outdoor experiences for young adults with cancer. Helps participants find support, face fears, and heal.

GYST

<http://gyst.com/>

Online resource to help you take care of important documents such as your will and power of attorney.

Imerman Angels

<http://www.imermanangels.org/>

Pairs individuals touched by cancer with other people who have fought and survived the same type of cancer (a Mentor Angel). These 1-on-1 relationships inspire hope and offer support from someone who is uniquely familiar with the experience of cancer.

Job Accommodation Network

<http://www.askjan.org/>

Offers tools to help patients understand the types of workplace adjustments that may help them continue working during and after cancer treatment.

LIVESTRONG

Late Effects of Cancer Treatment

<https://www.livestrong.org/we-can-help/healthy-living-after-treatment/late-effects-of-cancer-treatment>

Your Survivorship Care Plan

<https://www.livestrong.org/we-can-help/healthy-living-after-treatment/your-survivorship-care-plan>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

ONLINE RESOURCES FOR AYA PATIENTS AND SURVIVORS - [See NCCN Guidelines for Patients: Caring for Adolescents and Young Adults](#)

LIVESTRONG Care Plan

<http://www.livestrongcareplan.org/>

Interactive program that uses answers to a brief questionnaire to produce a basic survivorship care plan. The LIVESTRONG Care Plan is meant to be shared with the oncology team and used as a start for putting together a personal survivorship care plan.

Lotsa Helping Hands

<http://www.lotsahelpinghands.com/>

Free service designed to help friends and family organize support efforts. Includes a help calendar to schedule and sign up for specific report activities (shopping, rides to medical appointments, meal preparation, etc.) as well as a message board for sharing information.

MyLifeLine.org

<http://www.mylifeline.org>

Nonprofit organization that encourages cancer patients and caregivers to create free, customized websites to build an online support community of family and friends.

National Cancer Institute

Adolescents and Young Adults with Cancer: Survivorship

<http://www.cancer.gov/types/aya#5>

Facing Forward: Life after Cancer Treatment

<http://www.cancer.gov/cancertopics/coping/life-after-treatment/>

National Coalition for Cancer Survivorship

<http://www.canceradvocacy.org>

The oldest survivor-led cancer advocacy organization in the country, advocating for quality cancer care for all Americans and empowering cancer survivors.

The Patient Access Network Foundation

<http://www.panfoundation.org>

Provides help to underinsured patients for out-of-pocket expenses for life-saving medications. Patients must complete an application and meet certain insurance and income criteria to qualify for aid.

Patient Advocate Foundation Co-Pay Relief Program

<http://www.copays.org/>

Provides direct financial support for pharmaceutical co-payments to insured patients who financially and medically qualify.

Patient Advocate Foundation

<http://www.patientadvocate.org>

Provides professional case managers who serve as advocates for patients in dealing with insurance companies, employers, and/or creditors.

Rx Assist

<http://www.rxassist.org/patients>

Searchable online database of pharmaceutical companies' patient assistance programs

Surviving And Moving Forward: The SAMFund for Young Adult Survivors of Cancer

<http://www.thesamfund.org>

Non-profit organization that helps young adult survivors of cancer successfully transition into their post-treatment life, by providing financial support through the distribution of grants and scholarships.

Young Survival Coalition

<http://www.youngsurvival.org/>

Network of breast cancer survivors and supporters dedicated to the concerns and issues that are unique to young women and breast cancer.

End-of-Life Issues:

Aging with Dignity 5 Wishes:

<https://www.agingwithdignity.org/five-wishes>

Caring Connections

<http://www.caringinfo.org/i4a/pages/index.cfm?pageid=1>

Provides free resources and information to help people make decisions about end-of-life care and services.

Voicing My Choices Planning Guide for Adolescents and Young Adults

<http://www.agingwithdignity.org/voicing-my-choices.php>

Planning tool designed to help young people living with a serious illness to communicate their preferences to friends, family, and caregivers.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Table of Contents

Overview MS-2

Literature Search Criteria and Guidelines Update Methodology
..... MS-3

Risk Factors..... MS-4

Screening..... MS-5

Diagnosis..... MS-6

Management of AYA Patients With Cancer: Special Considerations MS-6

Age-appropriate Care..... MS-6

Treatment Options MS-7

Adherence to Treatment MS-9

Impact of Cancer and Its Treatment on Fertility MS-10

Fertility Preservation MS-12

Contraception During and After Treatment for Cancer MS-14

Management of Cancer During Pregnancy MS-15

Psychosocial and Behavioral Issues..... MS-17

Individual Function..... MS-17

Relationships MS-20

Socioeconomic Issues MS-21

Survivorship Issues MS-22

Late Effects in AYA Cancer Survivors MS-22

Long-term Follow-up MS-28

Palliative and End-of-life Care MS-29

Summary MS-30

Table 1. Age-specific SEER Incidences of Cancer by Cancer Site and Sex in the AYA Population (2010–2014)..... MS-31

References MS-32

Overview

Over the past 20 years, advances in cancer treatment have significantly improved survival rates for young children and older adults, but these improvements have generally not applied to adolescent and young adult (AYA) patients.^{1,2} One of the main reasons for the lack of improvement in outcomes is that AYA patients have a low rate of participation in clinical trials.^{1,3-6} In the United States, approximately 10% of patients 15 to 19 years of age and 1% to 2% of patients 20 to 39 years of age are enrolled in clinical trials.⁷ In addition to the low rate of participation in clinical trials, several other factors contribute to the poor outcome in AYA patients, such as: differences in disease biology, lack of consistency in treatment approaches, poor adherence or intolerance to therapy, lack of health insurance, delays in diagnosis, and physician's lack of familiarity with cancer in the AYA population.⁸ AYA patients also face unique developmental and psychosocial issues, which make adjustment to their disease, health maintenance, and financial hardships more challenging.^{6,9-12}

The biology, epidemiology, and clinical outcomes affecting AYA patients are usually different than those of younger and older patients with cancer.^{13,14} In addition, the genetic, physiologic, and pharmacologic changes associated with AYA patients may impact AYA patient's ability to tolerate cancer therapy and response to treatment. Moreover, short- and long-term toxicities impacting a young, independent patient—including the impact of treatment on fertility—may disincentivize treatment, leading to gaps in adherence and poor outcomes. Attention to these issues and providing options that empower the patient at the time of initial cancer treatment may result in more successful implementation of the planned therapy. Unlike comprehensive geriatric assessment, which is helpful to physicians in developing a coordinated treatment plan and understanding the functional needs of older

patients, no similar assessment has been reported for AYA patients. There are less evidence-based data to guide the treatment of AYA patients. AYA patients diagnosed with cancer should be recognized as a distinct age group that has unique medical and psychosocial needs.¹⁵ The distinct biology of disease as well as age-related issues in AYA patients should be considered in the treatment decision-making process.¹⁶

The AYA patient is generally defined as an individual 15 to 39 years of age at the time of initial cancer diagnosis.^{6,17} Nearly 70,000 patients in this age group are diagnosed with cancer each year in the United States, over 7 times more patients than those diagnosed who are younger than 15 years of age.¹⁷ Compared to children younger than 15 years, 5-year relative survival in AYA patients is worse for those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), non-Hodgkin's lymphoma (NHL), astrocytomas, Ewing sarcoma, rhabdomyosarcoma, or osteosarcoma.¹⁸ Additionally, for Ewing sarcoma, outcomes are worse for patients ≥18 years of age compared to patients <18 years.¹⁹⁻²¹ On the other hand, 5-year relative survival is better in AYA patients with medulloblastomas and germ-cell tumors compared to in children with these tumors, possibly reflecting biologic differences in the tumors of each age group. Compared to adults 40 years and older, AYA patients tend to have better survival rates, except for those with breast and prostate cancer.¹⁸ Increasing age is associated with poorer prognosis in AYA patients with AML, NHL, Burkitt and Burkitt-like lymphoma, or rhabdomyosarcoma.²² Female AYA patients tend to have better 5-year relative survival compared to male AYA patients.¹⁸

The spectrum of cancer types that affect the AYA population is unique and different from those that affect the pediatric and older population. Cancer is the leading cause of death among the AYA population,

excluding homicide, suicide, or unintentional injury.^{8,23} Lymphomas, melanoma, testicular cancer, female genital tract malignancies, thyroid cancer, bone and soft tissue sarcomas, leukemias, central nervous system (CNS) cancers, breast cancer, and non-gonadal germ cell tumors account for 95% of the cancers in this age group.^{1,24} The frequency and incidence of distribution of cancer types is also dramatically different across the age spectrum of AYA patients. See Table 1.

Quality care for AYA patients with cancer is tied to timely detection and initiation of treatment, adherence to treatment, and access to a multidisciplinary team of health care professionals who are well-versed in the specific developmental issues relevant to this patient population.^{25,26} These issues include fertility, long-term side effects, psychosocial and socioeconomic issues, transportation to clinic appointments, maintaining school and work obligations, child care, treatment adherence, and the unique biology of disease. The relative importance of these issues varies considerably across the broad age range defined as AYA. Certain institutions have established centers specialized in accommodating the specific needs of AYA patients. A retrospective population-based analysis in California found that while the percentage of AYA patients who received care from a specialized cancer center increased over the past 20 years (27% in 1991 to 43% in 2014), a minority of AYA patients receive care at specialized cancer centers.²⁷ Referral of patients to AYA centers of excellence should be considered if feasible.

The goals of the NCCN Guidelines® for Adolescent and Young Adult Oncology are to identify issues specific to AYA patients and recommend interventions unique to these patients; educate physicians regarding the prevalence of cancer in the AYA population and its long-term consequences; identify special considerations related to the

management of cancer in AYA patients with the aim of improving treatment tolerance, adherence, and clinical outcomes; and promote participation in clinical trials as well as enrollment on tumor banking and biologic protocols.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Adolescent and Young Adult Oncology, an electronic search of the PubMed database was performed to obtain key literature in Adolescent and Young Adult Oncology published between March 3, 2016 and March 1, 2017, using the following search terms: cancer infertility, cancer fertility, cancer AND adolescent, or cancer AND young adult. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.²⁸

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; Validation Studies; and Practice Guidelines.

The PubMed search resulted in 385 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Risk Factors

With rare exceptions, cancer appears to arise sporadically in most AYAs with a negative family history of cancer. There are no established risk factors for the majority of cancer diagnoses before 30 years of age.²³ Toxic and environmental exposures that cause cancer in AYAs include: 1) chemotherapy and/or radiation therapy (RT) leading to second malignancies in patients treated for cancer during childhood or young adulthood; 2) predisposition to clear cell adenocarcinoma of the vagina or cervix in patients with maternal exposure to diethylstilbestrol; and 3) melanomas induced by ultraviolet light. Infections that predispose AYAs to cancer include cervical carcinoma following exposure to human papillomavirus (HPV), HL and Burkitt lymphoma following Epstein-Barr virus (EBV) infection, and Kaposi sarcoma and NHL in patients with human immunodeficiency virus (HIV).²³

Familial cancer syndromes, associated with germline mutations in a variety of genes, affect only a small minority of AYA patients. However, these syndromes greatly increase the risk for cancer during adolescence and young adulthood. Referral for genetic and familial risk assessment and counseling is recommended as appropriate based on clinical history, family history, and/or histologic diagnosis.

Young women with germline mutations of *BRCA1/2*, *TP53* (Li-Fraumeni syndrome), or *PTEN* (Cowden's syndrome), or those who have received mantle field RT for HL are at an increased risk of developing breast cancer during young adulthood.¹ Screening for breast cancer may be warranted in AYA patients with inherited or familial risk factors. See the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian](#).

In young adults, hereditary polyposis and nonpolyposis syndromes, inflammatory bowel disease, and radiation exposure are predisposing factors for developing colorectal cancer. Hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) is an autosomal dominant syndrome caused by mutations in one of the four *MMR* genes (*MSH2*, *MLH1*, *MSH6*, or *PMS2*), and is associated with colon cancer developing in the AYA population.¹ Familial adenomatous polyposis (FAP) is an autosomal dominant disease caused by germline mutations in the *APC* gene. This syndrome is associated with the presence of thousands of colonic polyps and with the development of colon cancer in most affected patients by 40 years of age. Desmoid tumors are considered to be the most common extracolonic manifestations of FAP, and may be the presenting manifestation of FAP in AYA patients.²⁹ Screening for colorectal cancers may be warranted in AYA patients with inherited or familial risk factors. See the [NCCN Guidelines for Colorectal Cancer Screening](#).

AYA patients with Li-Fraumeni syndrome (resulting from germline mutations in the *TP53* tumor suppressor gene) or germline mutations in the retinoblastoma (*RB*) gene are at a higher risk of developing osteosarcoma and rhabdomyosarcoma.³⁰ Sarcomas represent 25% of tumors in *TP53* mutation carriers. AYA individuals with germline mutations in the *RB* gene have often been treated for retinoblastoma during early childhood.³¹ AYAs with a family history of Li-Fraumeni syndrome have a higher risk of developing not only sarcomas but a wide variety of malignancies, including leukemia, brain tumors, breast cancer, and adrenocortical carcinoma before 40 years of age.³² See the [NCCN Guidelines for Soft Tissue Sarcoma](#).

Patients with mutations in the succinate dehydrogenase (*SDH*) gene are at risk for paraganglioma and pheochromocytoma, gastrointestinal stromal tumors (GISTs), renal clear cell carcinoma, and papillary



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

thyroid carcinoma. Testing for germline mutations in the *SDH* subunit should be considered for AYA patients with wild-type GISTs lacking *KIT* or *PDGFRA* mutations.^{33,34} Patients with germline mutations in neurofibromatosis type I (*NF1*) carry a 10% lifetime risk for malignant peripheral nerve sheath tumors, as well as an increased risk for other malignancies including GISTs and early breast cancer in females.³⁵

Multiple neuroendocrine neoplasia (MEN) syndromes (MEN1 and MEN2) are autosomal dominant syndromes characterized by the development of endocrine tumors. MEN1 is caused by a germline mutation or inactivation of the tumor suppressor gene *MEN1*, whereas MEN2 is associated with germline tumors in the *RET* proto-oncogene.^{36,37} MEN1 is associated with the development of pituitary, parathyroid, and pancreatic neuroendocrine tumors.³⁸ Testing for MEN1 should be considered for patients with two or more MEN-associated tumors or in patients with one MEN-associated tumor and a relative with MEN1. MEN2 is further subdivided into MEN2A and MEN2B. Both of these subtypes are associated with a high risk of developing medullary thyroid carcinoma (MTC).³⁹ Most patients with MEN2B have mucosal neuromas or intestinal ganglioneuromas and pheochromocytoma in addition to MTC.³⁹ Testing for MEN2A should be considered for patients with two or more MEN2A-associated neoplasms or in patients with a close relative with MEN2A-associated neoplasms. Testing for MEN2B should be considered for patients with MTC, pheochromocytoma, mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, distinctive facies with enlarged lips, “marfanoid” body habitus, or inability to cry tears. See the [NCCN Guidelines for Neuroendocrine Tumors](#).

HPV infection has been associated with cervical cancer and few other non-cervical cancers, including anal and oropharyngeal cancers.^{40,41} Recent increase in the incidence of oropharyngeal cancers in the

United States has been attributed to HPV infection.^{42,43} Randomized clinical trials have demonstrated the efficacy of HPV vaccination against cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and oral HPV infections in women and men 15 to 25 years of age.⁴⁴⁻⁴⁶ In the PATRICIA trial, the efficacy of HPV vaccine against all cervical intraepithelial neoplasia associated with HPV-16/18 was highest in the 15 to 17 years age group and progressively decreased in the 18 to 20 years and 21 to 25 years age groups, suggesting that early HPV vaccination could substantially reduce the incidence of HPV-associated cancers in the AYA population.⁴⁵ HPV immunization (if not previously administered) is recommended for all males 9 to 21 years of age and females 9 to 26 years of age, since the vaccine has been shown to prevent cervical carcinoma and anal intraepithelial neoplasia.^{47,48} The Advisory Committee on Immunization Practices also recommends that men who have sex with men or who have immunocompromising medical conditions (such as cancer) be vaccinated through age 26.^{47,48}

Screening

AYA patients should be made aware of the importance of early diagnosis and self-examination of the skin, breasts (for females), and testicles (for males) as recommended by the American Cancer Society. They should also be educated regarding the benefits of early detection and treatment.⁸ Cancer screening in some circumstances, particularly in cervical, breast, and colorectal cancers, can significantly reduce mortality if directed at the appropriate age group and if the results are interpreted and followed up appropriately.⁴⁹ However, there are no age-specific screening tests that have been developed that would increase early detection in AYA patients with cancer, and in some instances screening tests have been associated with false-positive results leading to false diagnosis and unnecessary treatments.⁵⁰



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

Therefore, it is necessary to assess the potential risks and benefits of cancer screening in the AYA population.

Diagnosis

The onset of new symptoms in AYA patients may not immediately trigger evaluation for malignancy, due to the relatively low incidence of cancer in this age group and the resulting low index of suspicion on the part of patients, their families, and primary care providers. AYAs are at a higher risk of delayed cancer diagnosis, which may result in a more advanced stage of cancer that requires more therapy and is associated with a worse prognosis.⁸ Some studies have reported that adolescents experience longer lag times (interval between symptom onset and diagnosis) than children.⁵¹⁻⁵³ Lack of health insurance, inexperienced physicians, and workup that is inappropriate for the patient's age are some causes of delayed diagnosis in AYA patients, though more research is needed on these contributing factors.⁶ In a retrospective analysis of 503 patients aged 15 to 29 years with previously untreated cancer, the advanced stage of cancer at diagnosis and lack of health insurance were significantly associated with longer lag times.⁵⁴ Those with public or no health insurance had longer lag times than those with private health insurance in most of the cancers evaluated. Patients with leukemia and NHL had shorter lag times (2 to 5 weeks) than those with sarcomas and thyroid cancer (20 to 24 weeks), irrespective of the insurance type. In addition to health insurance, education and employment status are also likely to influence lag time, although these factors were not evaluated in this study.

Management of AYA Patients With Cancer: Special Considerations

AYA patients should be managed by a multidisciplinary team of providers with expertise in cancer treatment and management of

specific developmental issues such as fertility, education, career development, employment, family planning, pregnancy, sexually transmitted diseases, and tobacco, alcohol, and substance abuse. Given the rarity of several tumor types diagnosed in this population, all AYA patients should be offered and encouraged to participate in tumor banking studies and multicenter clinical trials, when available.

All AYA patients should undergo comprehensive assessment following the diagnosis of cancer, which should include psychosocial assessment, discussion of risks of infertility associated with cancer and its treatment, the use of and education concerning fertility preservation and contraception, and genetic and familial risk assessment as appropriate based on clinical history, family history, and/or histologic diagnosis. Age- and developmentally appropriate information related to cancer should be provided and women of childbearing potential must receive a pregnancy test prior to the start of therapy.

Age-appropriate Care

AYA patients can be treated either at pediatric or at adult cancer centers.²⁵ Retrospective analyses have shown that AYA patients with certain pediatric-type cancers, such as ALL,^{22,55-58} rhabdomyosarcoma,⁵⁹ and Ewing sarcoma,⁶⁰ have superior outcomes when treated with pediatric protocols. Alternatively, there is a lack of compelling evidence that pediatric protocols improve outcomes in AYA patients with AML, HL, and NHL.⁶¹⁻⁶³

As mentioned earlier, the low rate of participation in clinical trials is one of the main reasons for the lack of improvement in outcomes in AYA patients with cancer.^{1,3,4,22} A review of 30 studies of adolescents with cancer (ages 15–19 years) showed that 5% to 34% of these patients enrolled in clinical trials.²² In patients aged 20 to 25 years, clinical trial enrollment further decreases to approximately 2%.⁶⁴ Care should be



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

provided at medical centers with broad access to clinical trials (standard-of-care registry trials and trials evaluating novel therapies).²⁵ Pediatric cancer centers enroll more adolescents into clinical trials (35% vs. 12% at non-pediatric cancer centers), and AYA patients treated at pediatric cancer centers have a higher rate of clinical trial enrollment (26%) compared to those treated at adult cancer centers (4%).⁶⁵⁻⁶⁷ Parsons et al reported that AYA patients who are treated by non-pediatric oncologists are less likely to be enrolled in clinical trials.⁶⁸ Nevertheless, a substantial number of AYA patients with pediatric malignancies are not being treated at pediatric cancer centers.^{22,69,70}

The treatment and appropriate location of care vary with the type of cancer as well as with the availability of family, community, and institutional support.^{8,71} Most importantly, AYA patients should be evaluated at medical centers with extensive experience in treating cancer in this patient population and at centers that have access to supportive care services (psychosocial/educational support and fertility preservation) specific to the AYA population as well as to medical subspecialty services appropriate to the cancer diagnosis, such as orthopedic surgeons with experience in limb-sparing surgery for patients with extremity sarcomas.²⁵ In a supportive care needs survey that assessed the information and service needs of young adults with cancer at a single institution, the majority of young adults with cancer identified the following information as most important: information on their specific malignancy, effects of treatment on fertility, information on maintaining a healthy diet, and exercise/physical fitness during cancer treatment.⁷² Cancer centers should adopt the appropriate evidence-based approach, which includes adult centers implementing treatment based on pediatric protocols that have demonstrated superior outcomes in AYA patients and pediatric centers adopting adult regimens that have demonstrated benefit in this patient population.

Treatment Options

Selected AYA patients may tolerate more intensive therapies than older patients, since they have fewer comorbid conditions that limit the intensity of treatment in some older adults.⁸ Dose-intensive and dose-dense treatments are associated with improved outcomes in some malignancies.^{19,73,74} Therefore, more intensive therapy may be considered for every AYA patient if such a regimen exists for that particular disease and there are no contraindications.

Treatment-related issues in AYA patients may differ from those of pediatric or older adult patients due to the distinct biology of the disease.¹³ Physical and physiologic changes, such as changes in body composition, size and maturity of organs, and hormones associated with the normal pubertal process, may directly affect the drug disposition, drug efficacy, and toxicity of chemotherapy in AYA patients.⁷⁵ Appropriate management of symptoms and side effects to reduce the severity and toxicity of treatment should be an integral part of the management of AYA patients.⁷⁶ Surgery, RT, chemotherapy, and hematopoietic stem cell transplant (HSCT) are the main treatment options for patients who are able to tolerate curative treatment. All of these options are associated with both acute and late side effects.^{8,77}

Surgery

Surgery plays an important role in the management of cancer in AYA patients, especially in breast and thyroid cancer, melanoma, bone, and soft tissue sarcomas that are more common in AYA patients. Adolescent patients, whose bodies are still developing, may be more affected by some surgical procedures than older patients who are already at or near their full body size.⁸ The extent of surgery is dependent on the type and location of cancer. In some cases, extensive surgery requiring removing part or all of an organ or limb may be necessary. With advances in surgical techniques and

chemotherapy, limb-sparing surgery is feasible for the majority of patients with extremity sarcoma and osteosarcoma.⁷⁶ It is imperative that surgery should be performed in high-volume centers by surgeons with expertise in the management of AYA patients, with access to rehabilitative services to ensure that function is preserved as much as possible.

Radiation Therapy

RT is associated with an increased risk for late mortality; development of second malignancies; pulmonary, cardiac, and thyroid dysfunction; and chronic health conditions and growth abnormalities.⁷⁸ AYA patients receiving RT to testes or ovaries are at risk of developing infertility later in life.⁷⁹ Women with HL who receive chest RT between 10 and 30 years of age are at increased risk of developing breast cancer.⁸⁰ Cranial RT is associated with short stature, cognitive processing difficulties, and poor physical function, which contribute to lower rates of employment, independent living, and marriage among AYA cancer survivors.⁸¹ Adolescents are more vulnerable to RT-induced spinal cord dysfunction, presumably because of elongation of the cord during the growth spurt.⁸²

Chemotherapy

Pain, fatigue, nausea, vomiting, mucositis, hair loss, infection, and myelosuppression are some of the acute side effects of chemotherapy. Reversible toxicities do not necessarily warrant dose reductions. See the NCCN Guidelines for Supportive Care (available at www.NCCN.org) for the management of treatment-related toxicities. Every attempt should be made to maintain dose intensity unless it is contraindicated. Dose reductions are often based on avoiding severe, irreversible organ damage. Significant end-organ damage may compromise long-term function and quality of life in AYA patients. Maximum cumulative dosing parameters are often established for a

patient to reduce the risk of significant irreversible damage. Monitoring of cumulative dosing and dose schedule along with intensive screening is essential for patients receiving chemotherapy regimens associated with irreversible organ damage and/or infertility.

Anticipatory nausea and vomiting (ANV), also known as conditioned, learned, or psychological nausea and vomiting, is reported to occur before chemotherapy in approximately 20% of patients at any one chemotherapy cycle and in 25% to 30% of patients by their fourth chemotherapy cycle.⁸³ Younger patients (younger than 50 years of age) may be more susceptible to ANV, because they generally receive more aggressive chemotherapy and have poorer emesis control than older patients.⁸³ Behavioral therapy has been used in patients with ANV.⁸⁴ See the [NCCN Guidelines for Antiemesis](#).

Alkylating agent-based chemotherapy is associated with a higher risk of infertility in both male and female patients.⁷⁹ See the section on *Impact of Cancer and Its Treatment on Fertility*. Anthracycline-based chemotherapy is associated with cardiac dysfunction, whereas neurotoxic chemotherapies such as methotrexate and cytarabine can result in CNS dysfunction.⁷⁶ Bleomycin-induced pulmonary toxicity is well-documented in patients with HL treated with bleomycin-containing chemotherapy regimens.⁸⁵ Higher cumulative doses of cisplatin, ifosfamide, or epipodophyllotoxins are associated with hearing loss, renal dysfunction, and secondary AML, respectively.⁸⁶⁻⁸⁹ See also the section on *Late Effects in AYA Cancer Survivors*.

Hematopoietic Stem Cell Transplant

HSCT is a potentially curative treatment option for an increasing number of AYA patients with leukemias and lymphomas.⁹⁰ Graft-versus-host disease (GVHD), chronic immunosuppression, and gonadal dysfunction in males and females related to high-dose

conditioning chemotherapy and RT are the major post-transplant complications associated with HSCT.^{76,77}

Chronic GVHD has been identified as the leading cause of non-relapse mortality in HSCT survivors.⁹¹ AYA patients are at a higher risk of developing chronic GVHD than younger children.⁹² Patient age older than 15 years (children younger than 5 years had a probability of less than 14% compared to a probability of 44% for patients older than 15 years) and the use of total body irradiation (TBI) were significantly associated with an increased likelihood of developing chronic GVHD following allogeneic HSCT.⁹³ Patients receiving peripheral stem cells during their transplant procedure have a greater risk of chronic GVHD compared to those who received bone marrow transplant.⁹⁴ A report from the Bone Marrow Transplant Survival Study demonstrated that chronic GVHD had a significant impact on the overall health status of HSCT survivors, particularly in the areas of functional impairment, activity limitation, and pain.⁹⁵ This study also demonstrated that resolution of chronic GVHD resulted in long-term health outcomes that were comparable to survivors who were never diagnosed with chronic GVHD.

HSCT survivors are also at increased risk for late complications, which include recurrent infections, secondary cancers, cardiac dysfunction, growth failure, weight loss, neurocognitive delay, and other end-organ dysfunction.^{76,77,96} In addition, the incidence of severe or life-threatening chronic health conditions, endocrine complications, or secondary cancers is also higher among HSCT survivors than in non-cancer populations and patients with cancer who are treated conventionally.⁹⁰ Allogeneic HSCT survivors irradiated at 30 years or younger are at higher risk of developing secondary solid cancers.⁹⁷

These findings highlight the increasingly recognized need for long-term follow-up care that incorporates screening and surveillance of AYA survivors of HSCT.

Adherence to Treatment

Adherence is defined as the extent to which a person's behavior corresponds with agreed recommendations from a health care provider. Nonadherence to recommended treatment and follow-up care contributes to poor clinical outcomes in AYA patients with cancer.^{98,99} Failure to keep up with appointments can lead to delayed identification of side effects, complications, or secondary cancers.

Nonadherence to treatment regimens has been an ongoing problem among patients with cancer, and the prevalence of nonadherence has been consistently higher among adolescents compared to younger or older patients with cancer.⁹⁸ Nonadherence to oral chemotherapy contributes to reduced treatment efficacy and increased risk of recurrence. Available evidence from clinical trials that have included AYA patients with leukemia and lymphoma suggests that a substantial portion of AYA patients with cancer (27%–63%) have difficulties adhering to their oral treatment regimens.^{98,99}

Nonadherence to other components of cancer treatment (eg, failure to keep appointments for treatment or follow-up, refusing medical examinations, failing to prepare for procedures or therapy) was also identified in AYA patients. Treatment nonadherence in clinical trials can also interfere with adequate evaluation of the efficacy of a given treatment regimen, which in turn can invalidate the results of a clinical trial.

Risk factors for nonadherence among AYA patients include patients' emotional functioning (depression and poor/low self-esteem), personal



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

beliefs (perceived severity of cancer diagnosis and the necessity of intervention), growing independence, competing obligations (school, work, and family), and lack of insurance and appropriate psychosocial support.¹⁰⁰ In a randomized controlled trial, video game intervention significantly improved treatment adherence to prophylactic antibiotics among AYAs with acute leukemia, lymphoma, and soft tissue sarcoma.¹⁰¹ Additional studies evaluating the effect of interventions to improve adherence in AYA patients with cancer are needed.⁶

Risk assessment for non-adherence among AYA patients should include consideration of patient maturity, independence, unmet psychosocial and physical needs, and treatment side effects.¹⁰² For AYAs presumed to be at high risk of nonadherence, implementation of individualized interventions such as additional supportive care resources (eg, social work, psychology, palliative care) to promote adherence may improve outcomes in AYA patients with cancer. The patient's personal support system (family and friends) should be mobilized and educated to assist in relieving some of the burdens of care and to positively encourage the patient to maintain adherence to therapy. In the absence of data from studies evaluating the effect of interventions to improve adherence in AYA patients with cancer, findings from studies involving AYA patients with other chronic diseases may be able to be extrapolated to this patient population. For example, a meta-analysis showed that behavioral and multicomponent interventions have a moderate effect on improving treatment adherence in children (2–15 years of age) with chronic conditions such as diabetes, asthma, and cystic fibrosis.¹⁰³

NCCN Recommendations to Promote Adherence

- Educate about the expectations of treatment, and explain the patient's responsibility to adhere to treatment. Engage in collaborative treatment decision-making with the AYA patient.

- Provide education and/or guidance about each medication prior to the start of treatment and every time there is a change in treatment. Review the list of medications as well as their dose, purpose, and adverse effects.^{98,99}
- Modify treatment protocol (eg, simplify dosing schedule, change timing and frequency of medication or method of administration), when medically possible, to fit into an AYA patient's lifestyle and normal activities.^{98,99}
- Provide access to systematic and standardized symptom management for side effects related to cancer treatment.^{98,99} See the NCCN Guidelines for Supportive Care (available at www.NCCN.org).

Impact of Cancer and Its Treatment on Fertility

Infertility is a major consequence of cancer and its treatment in both males and females.¹⁰⁴⁻¹⁰⁷ The impact of cancer treatment on fertility is related to the age of the patient at the time of diagnosis and treatment, and is dependent on the type, duration, and dose intensity of treatment. Alkylating agent-based chemotherapy, high-dose cranial RT that can impair hypothalamic pituitary function, and targeted RT to the uterus, ovaries, or testes are primary risk factors for gonadal dysfunction and decreased fertility in both females and males.¹⁰⁸⁻¹¹⁴ Gonadal exposure to low-dose RT can result in oligospermia or azoospermia in males. Higher-dose RT is associated with both ovarian and uterine dysfunction in women.

Young women with HL treated with chemotherapy are at risk of developing premature ovarian failure, irrespective of their age at the time of treatment (38% for those diagnosed between 30 and 40 years of age; 37% for those diagnosed between 9 and 29 years of age). The cumulative risks for premature ovarian failure are much higher after alkylating agent-based chemotherapy.^{115,116} In a large cohort of women

treated between the ages of 15 and 40 years for HL, the cumulative risk of premature ovarian failure after alkylating agent-based chemotherapy was 60% compared to only 3% or 6% after non-alkylating agent-based chemotherapy.¹¹⁶ Independent risk factors for acute ovarian failure include increasing RT doses to the ovaries and exposure to procarbazine and cyclophosphamide at 13 to 20 years of age.¹⁰⁹ An analysis of 590 women who were diagnosed with HL before 18 years of age showed that RT to the pelvis was associated with decreased incidence of parenthood (HR, 0.66; 95% CI, 0.48–0.90; $P = .01$).¹¹⁷

Among young women treated with adjuvant chemotherapy for breast cancer, the risk for premature menopause is significantly higher for women older than 35 years with newly diagnosed breast cancer treated with chemotherapy.^{118,119} Similarly, among female survivors of HL diagnosed between 14 and 40 years of age, women who were 22 to 39 years of age at first treatment were at a higher risk of developing premature menopause after treatment compared to younger patients (14–21 years).¹²⁰ Treatment with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)/ABV (doxorubicin, bleomycin, and vinblastine) significantly increased the risk of ovarian failure. After 10 years of treatment, the actuarial risk of premature menopause was 64% after high cumulative doses ($>8.4 \text{ g/m}^2$) and 15% after low doses ($\leq 4.2 \text{ g/m}^2$) of procarbazine.¹²⁰

In males treated with alkylating agent-based chemotherapy and RT to testes, germ cell dysfunction with resultant infertility is more common than Leydig cell dysfunction and testosterone insufficiency.¹²¹ Leydig cell dysfunction is characterized by increased plasma concentrations of luteinizing hormone (LH) combined with low levels of testosterone. Germ cell dysfunction is associated with reduced testicular volume, increased follicle-stimulating hormone (FSH) concentrations, and reduced plasma concentrations of inhibin B. Leydig cell dysfunction

occurs at RT doses higher than those associated with germ cell dysfunction. AYA men treated with testicular RT $\geq 20 \text{ Gy}$ are at high risk for Leydig cell dysfunction, whereas testicular RT $\geq 2 \text{ Gy}$ can impair spermatogenesis resulting in permanent azoospermia.¹²¹ TBI used as part of high-dose conditioning therapy prior to HSCT can also affect the testes, resulting in permanent infertility in the majority of AYA men.⁷⁹

Azoospermia is associated with chemotherapy and radiation. Whether it is transient or permanent depends on the type of treatment involved, with radiation and alkylating agents posing the greatest risk for long-term damage.¹²² Azoospermia has been reported in more than 90% of men receiving procarbazine-based chemotherapy regimens such as MOPP and may not resolve over time, resulting in permanent infertility.¹²³ Alternatively, the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen has been shown to be less gonadotoxic, with a vast majority of patients regaining normal fertility after completion of treatment.¹²⁴ Cisplatin-based chemotherapy for testicular cancer is associated with temporary azoospermia in most men, with a recovery of spermatogenesis in about 50% to 80% of patients after 2 to 5 years.¹²⁴ RT $> 2 \text{ Gy}$ to the testes, moderate- to high-dose alkylating agent chemotherapy (MOPP > 3 cycles), higher cumulative alkylating agent dose (busulfan $> 600 \text{ mg/m}^2$, cyclophosphamide $> 7.5 \text{ g/m}^2$, or ifosfamide $> 60 \text{ mg/m}^2$), or any alkylating agent combined with RT to testes or TBI are considered as risk factors for oligospermia and azoospermia.^{104,112} Pelvic RT and cumulative cyclophosphamide doses $> 9.5 \text{ g/m}^2$ are associated with a high risk of permanent infertility as seen in male patients with NHL, Ewing sarcoma, and soft tissue sarcomas.^{125,126} Retroperitoneal lymph node dissection is also associated with infertility in men with testicular cancer.¹²⁷

The NCCN Guidelines recommend discussing the risks of infertility due to cancer and its treatment with all patients at the time of diagnosis, prior to initiating treatment. This is especially important for patients who will be starting therapies with a high risk of affecting fertility, as described above.

Fertility Preservation

Fertility preservation is an issue of crucial importance in AYA patients and should be an essential part in the management of their cancer.^{16,79,128-132} The ASCO Clinical Practice Guidelines recommend that providers discuss the options for fertility preservation with all new cancer patients at the time of diagnosis.¹³³ Nevertheless, fertility preservation is currently one of the most under-prescribed and least implemented services in AYA patients with cancer.^{79,128,134} A study that reviewed 231 records of AYA patients with leukemia/lymphoma, sarcoma, or breast or testicular cancers showed that infertility risk was discussed 26% of the time, and fertility preservation options were discussed 24% of the time.¹³⁵ However, it is possible that more discussions about infertility occurred without having been documented. Another study that analyzed the electronic medical records of 454 AYA patients at a single cancer center showed that the risk of infertility was discussed with 83% of patients, with women more likely to be informed than men (OR, 3.57; 95% CI, 1.33–9.60; $P = .01$).¹³⁶ A study of 146 adolescent males at risk for infertility due to cancer treatment across 8 different pediatric oncology centers found that only 53.4% attempted to bank sperm, with 43.8% successfully banking. Parent or medical team recommendation was associated with increased likelihood of sperm banking completion.¹³⁷

Psychosocial providers can assist patients and families in the decision-making process about fertility preservation, particularly when

AYA patients are distressed about the potential infertility associated with cancer treatment.¹³³ The Oncofertility Consortium, a group of clinicians and researchers in the United States, was formed in 2007 to address reproductive barriers facing AYA patients and to identify research priorities in this area.¹³⁸ Future aims that were developed during a 2011 meeting are as follows:

- Determine optimal techniques for cryopreservation of reproductive tissue and gametes
- Further investigate in vitro follicle maturation in primates
- Investigate AYA patients' psychosocial needs as part of the fertility preservation plan
- Improve patient-provider communication regarding fertility preservation
- Develop and carry out multicenter studies, utilizing the preexisting infrastructure of the National Physicians Cooperative

Options for Females

Ideally, fertility preservation should be initiated prior to the start of treatment. However, in some situations, when it is impractical or impossible to pursue fertility preservation prior to initiating therapy, it may be appropriate to readdress later in the course of treatment.

Oophoropexy and embryo cryopreservation after in vitro fertilization (IVF) are two established options for fertility preservation in females.¹³³ Oophoropexy involves surgically displacing the ovaries out of the RT field to minimize ovarian damage and has been shown to preserve ovarian function.¹³⁹ Embryo cryopreservation after IVF has been highly successful in women younger than 40 years of age.^{79,128} However, this method requires a male partner or sperm donor who is available with short notice. In one study that assessed pregnancy outcomes following embryo cryopreservation, letrozole was used in combination with FSH to protect patients with breast cancer against the harmful effects of

increased estrogen.¹⁴⁰ Out of 33 women, the live birth rate was 45%, with 39% of live births resulting in twins. These rates are not significantly different from those for infertile couples not affected by cancer, except for implantation rate, which was greater in the patients with breast cancer (40.7% vs. 26.1%). A little over half (55%) of the embryos were transferred to a gestational carrier, with no significant differences in outcomes (ie, implantation, live birth, twinning rates) between self-transfers and gestational carriers.

Mature oocyte cryopreservation is an alternative for single women, but, like embryo cryopreservation, requires hormone stimulation.^{79,128} Evidence from randomized trials¹⁴¹⁻¹⁴⁴ and a meta-analysis¹⁴⁵ suggest that IVF with cryopreserved oocytes results in fertilization and pregnancy rates similar to that of fresh oocytes. Oocyte cryopreservation is no longer considered investigational according to guidelines from the American Society for Reproductive Medicine.¹⁴⁶

Ovarian tissue cryopreservation is a promising, but less well-studied strategy for female fertility preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the patient is pre-pubertal. This technique does not require hormonal stimulation, so there is no long delay in initiation of treatment.⁷⁹ While evidence supporting the effectiveness and safety of ovarian tissue cryopreservation is scarce, a few systematic reviews have supported its use for fertility preservation in cancer patients.^{147,148} This procedure would not be appropriate for some women with cancer where there is a potential for reintroduction of malignant cells that could occur with grafting. While ovarian tissue cryopreservation is still considered investigational at some institutions, it may be discussed as an option for fertility preservation, if available. Xenotransplantation of ovarian tissue is currently under investigation.¹⁴⁹

Some studies, including randomized trials, have evaluated the role of menstrual suppression with gonadotropin-releasing hormone (GnRH; also known as luteinizing hormone-releasing hormone [LHRH]) agonists to preserve ovarian function during chemotherapy.¹⁵⁰⁻¹⁵⁸ Some meta-analyses have shown that GnRH agonist may be beneficial for fertility preservation.¹⁵⁹⁻¹⁶¹ However, the impact of these meta-analyses are limited by flaws such as only examining women with breast cancer and only including trials that were not adequately powered and did not utilize blinding and/or a placebo condition.^{162,163} Further, results from earlier meta-analyses were inconsistent, with some demonstrating a potential benefit of GnRH to preservation of ovarian function,¹⁶⁴⁻¹⁶⁶ while other reviews have been unable to come to this conclusion.^{167,168} There are also limited data available on the long-term impact of GnRH on preservation of ovarian function,¹⁵⁹ though a 5-year follow-up analysis of a randomized trial showed that administration of a GnRH agonist does not significantly impact premature ovarian failure or future pregnancy rate.¹⁵⁸ Therefore, though data suggest that menstrual suppression with GnRH agonists may protect ovarian function, further investigation is needed.

Other agents such as the progestin medroxyprogesterone and oral contraceptives may be used in women with hematologic malignancies who are at risk for menorrhagia, but this does not preserve ovarian function.¹⁶⁹ However, caution is needed in endometrial cancer survivors where progestin therapy has been associated with high rates of cancer recurrence,¹⁷⁰ which may be prevented by combining metformin with medroxyprogesterone.¹⁷¹

Options for Males

Semen cryopreservation before the start of treatment is the most reliable and well-established means of preserving fertility in AYA males with cancer.^{79,128} The success of sperm banking may be limited in some



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

patients, such as those with HL and testicular cancer, who may already have azoospermia associated with the disease. Depending on the type of chemotherapy, semen collection may be possible after initiation of chemotherapy; however, the impact of chemotherapy and RT on the risk of genetic defects in the offspring remains unknown.¹⁷²

Cryopreservation and subsequent transplantation of spermatogonial stem cells is experimental but may be an alternative option for some patients in whom semen cryopreservation is not possible.^{79,128} There is limited evidence regarding the efficacy of hormone suppression in reducing the risk of male infertility during chemotherapy.¹³³

Recommendation for Fertility Preservation

The NCCN Guidelines emphasize that fertility preservation, as well as sexual health and function, should be an essential component of the management of AYA patients, who may be at risk for infertility due to cancer treatments. Options for fertility preservation should be discussed with all patients prior to the start of treatment and providers should initiate referral to fertility preservation clinics within 24 hours for all patients who choose the option of fertility preservation. Local or institutional grants may be available to provide financial assistance with fertility preservation needs. Follow-up with a fertility specialist post-treatment may also be helpful for some patients. Referral to a mental health professional to assist with complex decision-making is recommended.

Females

- Oophoropexy should be considered for all female patients who will be receiving RT.
- Embryo or oocyte cryopreservation should be discussed, if it is possible to delay treatment long enough for a cycle of oocyte

stimulation, especially for patients with low- and intermediate-risk HL, low-grade sarcomas, and breast cancer.¹⁴⁶

- Ovarian tissue cryopreservation may be considered, if available.¹⁴⁷
- Medroxyprogesterone, oral contraceptives, or GnRH agonists can be used in protocols that are predicted to cause prolonged thrombocytopenia and thus present a risk for menorrhagia.¹⁶⁹
- Some data suggest that menstrual suppression with GnRH agonists may protect ovarian function.^{155,159,161} However, evidence that menstrual suppression with GnRH agonists protects ovarian function is insufficient, so this procedure is not currently recommended as an option for fertility preservation.

Males

- Discuss the possibility of sperm banking at the time of diagnosis. AYA patients can use either a local sperm bank or an available online sperm banking kit.
- Oncology centers that treat AYA patients should develop a system for offering sperm banking to all AYA patients in a systematic and patient-centered manner.

Contraception During and After Treatment for Cancer

Male condoms may be safely used by AYA males with cancer.¹⁷³ AYA women with cancer have unique contraception needs and the options are dependent on the type of cancer, its treatment, and treatment-related complications.¹⁷⁴ The NCCN Guidelines recommend discussion about the use of contraception prior to initiating therapy.¹⁷⁴

Long-acting reversible contraception (LARC) with intrauterine devices (IUDs) or implantable contraceptives are more effective than short-term contraceptive methods, which include the use of estrogen and progestin with various delivery systems.¹⁷⁵ LARC has been shown to be



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

superior to short-acting contraceptives in AYA women.^{176,177} In a study of 4167 women (14–45 years of age), LARC was associated with higher 12-month adherence rates than oral contraceptive pills (86% vs. 55%).¹⁷⁶ In a large, prospective study involving 7487 women, the contraceptive failure rate was significantly higher for those using oral contraceptive pills, patch, or ring compared to those using LARC (4.55 vs. 0.27), and the failure rates among women younger than 21 years were twice as great as in women 21 years of age or older.¹⁷⁷

The Society of Family Planning guidelines recommend the use of IUDs or implantable contraceptives for most women who are receiving treatment for cancer.¹⁷⁸ The use of any method of contraception is recommended for women who have been free of cancer for at least 6 months and have no history of hormonally mediated cancers, chest RT, anemia, osteoporosis, or venous thromboembolism (VTE).¹⁷⁸ The use of IUDs is considered the preferred first-line contraceptive option for women with a history of breast cancer, although for women treated with tamoxifen, a levonorgestrel-containing intrauterine system (IUS) may be preferable since it has been shown to reduce tamoxifen-induced endometrial changes without increasing the risk of breast cancer recurrence. A levonorgestrel-containing IUS may also be used to minimize menstrual blood loss in women with iron-deficiency anemia.¹⁷⁸

Due to the risk of VTE associated with the use of combined hormonal contraceptive methods, the U.S. Centers for Disease Control and Prevention recommend that the use of these contraceptive methods should be avoided in women of childbearing age with active cancer or who have been treated for cancer in the last 6 months.^{179,180}

Management of Cancer During Pregnancy

All women of childbearing potential must receive a pregnancy test prior to initiating therapy. Cancer is diagnosed in about 0.1% of pregnant

women and is the second most common cause of maternal death during pregnancy.¹⁸¹ Cervical, breast, thyroid and ovarian cancers, melanoma, lymphoma, and leukemia are the most common cancers diagnosed during pregnancy.^{182–185} These are also the most common cancers diagnosed in the AYA population.¹⁸⁶ An analysis of 1963–2007 data from the Swedish Multi-Generation Register and the National Cancer Register showed a lower-than-expected number of cancers diagnosed during pregnancy, and a rebound in the number of cases of melanoma, CNS cancers, breast cancer, and thyroid cancer in postpartum women.¹⁸⁵ This rebound may be due to changes in the mammary and thyroid glands being overlooked during the postpartum period. Despite some persisting beliefs, there is no evidence of pregnancy-associated relapse in female survivors of HL.¹⁸⁷

While there is limited research on the prognosis of cancer during pregnancy, a few meta-analyses and systematic reviews have suggested that the prognosis of certain cancers (eg, breast, melanoma, vulvar) may be worse when occurring concurrently with pregnancy compared to the same cancers occurring outside pregnancy.^{188–191} These results may be confounded by factors related to the patients' pregnancy, delays in diagnosis, and differences in treatment decisions, making a definitive conclusion difficult.

Accurate diagnosis of the type and stage of cancer using appropriate imaging studies (ultrasound, chest x-ray, and mammogram) with abdominal shielding and limiting fetal exposure to ionizing radiation is an essential step in the management of cancer during pregnancy.^{192–194} There is insufficient evidence regarding the safety of gadolinium-based contrast agents in pregnant women.¹⁹⁴ Surgery is possible at any time during pregnancy depending on the anatomical location of the tumor, although it may be beneficial to delay surgery, when possible, until after fetus viability.^{192,194} Selection of an appropriate treatment plan for

pregnant women is dependent on individual tumor biology and tumor stage, similar to the management of cancer in non-pregnant women. In addition to the disease characteristics in pregnant women, the gestational age of the fetus is a significant factor in the selection of treatment.¹⁹²

RT is contraindicated during pregnancy. However, in very rare instances when RT is necessary, it should be delivered in low therapeutic doses (with adequate uterine shielding to minimize fetal exposure) with the goals of controlling maternal cancer and providing the fetus the best chance for survival with normal development.¹⁹⁵ The dose to the fetus can be reduced by using modified RT administration techniques or adding additional shielding between the treatment machine and the patient.¹⁹⁵ Early collaboration among the radiation oncologist, medical physicist, medical and/or surgical oncologist, and obstetrician is essential. The American College of Radiology has developed guidelines with an objective to assist practitioners in identifying pregnancy, preventing unnecessary irradiation of pregnant AYA women, tailoring examinations to effectively manage RT dose, and developing strategies to quantify and evaluate the potential effects of RT delivered to patients who are pregnant.¹⁹⁶ In 2014, an international consensus panel made up of researchers and clinicians who are experts in treatment of cancer during pregnancy also developed guidelines for RT in women who are pregnant.¹⁹³

Chemotherapy should be avoided during the first trimester because of greater risk of teratogenic effects, which include major congenital malformations, impaired organ function, spontaneous abortions, and fetal death.^{194,197-200} While the use of chemotherapy during the second and third trimesters has not been associated with significant teratogenic effects, it may be associated with low birth weight, preterm labor, and intrauterine growth restriction.^{184,197,199,201-203} However, a multicenter,

prospective case-control study of children born to mothers with cancer (129 cases, 129 controls) showed no significant impact of chemotherapy treatment on cognitive, cardiac, and general development of the offspring.²⁰⁴ Potential benefits and risks of chemotherapy for both the mother and fetus must be carefully evaluated prior to initiation of treatment. Delayed treatment until after fetal maturity, with careful follow-up to rule out disease progression, is a safe option for women diagnosed with early-stage cancers.^{205,206} In some women diagnosed with advanced-stage disease with an urgent need to start chemotherapy in the first trimester, potential benefits and risks of chemotherapy for both the mother and fetus must be carefully evaluated prior to initiation of treatment.¹⁸⁴ Due to the severe teratogenic effects of methotrexate, it should not be used for the treatment of cancer in women at any stage of pregnancy.¹⁹⁹ Older-generation alkylating agents (eg, procarbazine, busulfan), thalidomide, lenalidomide, pomalidomide, and tretinoin are also considered teratogenic and are contraindicated during pregnancy.¹⁹³ The safety and efficacy of hormonal agents and targeted therapies have not yet been evaluated in well-controlled studies including pregnant women.^{192-194,207-209} At the present time, the use of such agents in pregnant women is not recommended.

Supportive care for the management of treatment-related side effects should be integrated into treatment planning based on the trimester of pregnancy. Granulocyte colony-stimulating factors for the management of neutropenia and antiemetics for the management of nausea and vomiting have been utilized in pregnant women without any significant side effects.^{193,208,210,211}

The panel members acknowledged that the management of cancer during pregnancy poses significant diagnostic and therapeutic challenges for both the patient and the physician. The guidelines

recommend that AYA women diagnosed with cancer during pregnancy require individualized treatment from a multidisciplinary team involving medical, surgical and radiation oncologists, gynecologic oncologists, obstetricians, and perinatologists as appropriate.^{184,193} Referral to tertiary cancer centers with expertise in the diagnosis of cancer during pregnancy and maternal-fetal medicine and knowledge of the physiologic changes that occur during pregnancy should be strongly encouraged.

Psychosocial and Behavioral Issues

AYA patients diagnosed with and treated for cancer have psychosocial issues that are distinct from that of pediatric and adult patients.^{6,9-12} AYA patients 20 to 29 years of age are significantly less likely to use professional mental health services than teens and older patients 30 to 39 years of age. AYA patients in the 20 to 29 years age group are also significantly more likely to report an unmet need with regard to receiving age-appropriate information about their cancer. Some of the challenges faced by AYA patients and survivors include maintaining an active and independent life, coping with treatment-related side effects and stress, seeking and understanding information, accepting cancer, and maintaining a positive attitude.²¹² AYA men and women go through developmental stages marked by rapid changes in cognitive and emotional growth, and these issues need to be considered while delivering developmentally appropriate psychosocial and supportive care to AYA patients.²¹³

Few measurement tools have been developed to better understand health-related quality of life in AYA patients with cancer.⁶ Palmer et al developed an AYA Oncology Psychosocial Screening Tool to assist clinicians in supporting psychosocial coping during active treatment and promoting healthy post-treatment survivorship in AYA patients. This

screening tool has four main areas: a distress thermometer, a checklist of “areas of concern,” a tick box for information provision, and signatures. Further validation of this tool and its use will help clinicians to improve psychosocial care for AYA patients, regardless of where they receive treatment.²¹⁴

Psychosocial needs for AYA patients should be assessed across the following domains: 1) individual function (psychosocial, emotional, and behavioral issues); 2) relationships (family, peers, and health care professionals); and 3) socioeconomic issues. Age and developmentally appropriate supportive care services and interventions should be utilized to address each of these domains.

Individual Function

Psychosocial Issues

AYA patients have to cope with cancer treatment while accomplishing key developmental tasks such as identity development, including sexual identity; peer involvement; initiating intimate and emotional relationships; establishing autonomy from parents; maintaining personal values; fostering self-esteem and resilience; and independently making decisions about their future that involve education, career, or employment.²¹⁵⁻²¹⁸ The impact of diagnosis and treatment of cancer on their physical appearance, sexual development, and sexual function can lead to shame, social isolation, and regressive behaviors if not addressed promptly. Cancer and its often intensive and lengthy treatments put AYA patients at risk for disruptions in their normal activities. Interruptions of school or work due to treatment will have negative consequences for their long-term career opportunities, financial status, and lifetime earnings.²¹² During the treatment period, AYA patients should have the opportunity to live as normal a life as possible, continue their education and/or careers, and participate in the many milestones of their lives.²¹⁹ Physical and/or occupational therapy

may help AYA patients transition back to a lifestyle appropriate for their age group.²²⁰

Emotional Issues

Cancer-related issues such as confrontation with mortality and loss of fertility can result in significant emotional distress and psychiatric symptoms such as depression and anxiety in AYA patients. These feelings are related to patients' cognitive capacity to understand the severity of their disease while sometimes lacking fully mature cognitive and emotional coping abilities.²¹² Psychological distress is significantly greater among AYAs compared with older adults.²²¹⁻²²⁵

In a longitudinal study that assessed the prevalence of psychological distress in 215 AYA patients with cancer (15–39 years of age) during the first year following diagnosis, distress symptoms exceeded population norms at the time of diagnosis and at 12-month follow-up.²²² In this study, 12% of AYA patients reported clinically significant chronic distress throughout the first 12 months following diagnosis and an additional 15% reported delayed distress.

In addition to distress, depression and anxiety are commonly experienced by AYA cancer survivors. An analysis from the Childhood Cancer Survivor Study (CCSS) showed that survivors of AYA cancer ($n = 2,589$) report higher rates of depression (OR, 1.55; 95% CI, 1.04–2.30) and anxiety (OR, 2.00; 95% CI, 1.17–3.43), compared to their siblings ($n = 391$).²²⁶ Another study of 5341 cancer survivors diagnosed at 25 years of age or earlier found that survivors were more likely to be prescribed antidepressants compared to age- and gender-matched controls (26.9/1000 person-years for survivors vs. 22.5/1000 person-years in controls; HR, 1.19; 95% CI, 1.12–1.28).²²⁷

The needs for information, counseling, and practical support were reported in 57%, 41%, and 39% of AYA patients, respectively, at 12 months after the diagnosis of cancer.²²⁴ Kazak et al reported that intensive cancer treatments during adolescence are associated with inferior psychosocial outcomes and health beliefs in survivors compared to their age-matched peers.²²⁸ Psychological problems are also associated with an increased risk for obesity and poor health behavior, which may increase future risk for chronic health conditions and secondary neoplasms.²²⁹

Behavioral Issues

AYA patients with cancer may engage in risky behaviors (tobacco, alcohol, cannabis, or substance use/abuse) that may impair their health. Older age at cancer diagnosis, lower household income, less education, no pulmonary-related cancer treatment, and no brain RT were independently associated with a statistically significant relative risk of smoking initiation.²³⁰ The risk factors associated with heavy drinking included fair or poor self-assessed health, depression, anxiety, somatization, activity limitations, and cancer-related fears and uncertainty.²³¹ Low perception of susceptibility to late effects, older adolescence compared to early adolescence, and worry were the strongest predictors of substance abuse.²³² While AYA patients may be aware of the complications associated with tobacco, alcohol, cannabis, or substance use/abuse during their treatment, they may not avoid them throughout their treatment as these habits make them feel normal and like part of their peer group. Clinicians working with this population need to be aware of this and address the issues in a sensitive and confidential manner.^{219,233}

Studies have shown increased rates of mental illness and cognitive impairment among adolescent cannabis users compared to adults with similar usage habits.²³⁴ Heavy or regular use of cannabis in adolescents

has been associated with impairments in attention, learning, memory, planning, and psychomotor speed. An earlier age of onset of cannabis use exacerbates these adverse effects. If an AYA patient chooses to continue use of cannabis, education on methods for lowering risk of adverse effects is recommended. For example, the patient may be counseled to avoid high tetrahydrocannabinol (THC)-content products, avoid synthetic cannabinoids, choose routes of administration other than inhalation of combusted cannabis, limit frequency of use, and never drive while impaired.²³⁵

AYA patients are also vulnerable to sexual and reproductive health complications that should be addressed prior to, during, and after completion of treatment.¹⁷⁴ Traditional risk-taking behaviors of AYA individuals coupled with a compromised immune system can put AYA patients with cancer and survivors at a greater risk of sexually transmitted infections. See the section on *Contraception During and After Treatment for Cancer* for more discussion of appropriate contraception choices for patients with cancer and survivors.

AYA patients have nutritional concerns that are different from those of children and adults, especially among younger patients in this population. Adolescents are dependent on their families for food preparation and may experience peer pressure when eating at school or with friends. Diet/nutrition information has been reported as an unmet need among AYA patients.¹⁰ Nutritional requirements and potential deficits should be evaluated based on the patient's age.

NCCN Recommendations For Supportive Care Services/Interventions for Psychosocial and Behavioral Issues

- Provide information about reliable online sources to access developmentally appropriate information related to their cancer. See *Online Resources for AYA Patients and Survivors* in the algorithm.
- For all AYA patients, provide counseling around decision-making regarding the risks of infertility associated with cancer and its treatment and the use of fertility preservation and contraception prior to initiating treatment.²³⁶
- Since the incidence of sexually transmitted infections peaks among AYAs 15 to 24 years of age, provide preventive health education about sexually transmitted diseases.²¹⁹
- Prescribe and provide nutrition and exercise recommendations for all AYA patients. Refer to a Registered Dietitian-Certified Specialist in Oncology.²³⁷
- Consider flexible treatment dates, consultation times, and procedures when possible to enable AYA patients to continue with their treatment without interrupting their school/work or other normal activities.²¹⁹
- Offer psychosocial support and counseling to help alleviate distress. See the [NCCN Guidelines for Distress Management](#).
- Refer AYA patients with cognitive dysfunction or other psychiatric symptoms (eg, depression or anxiety) to a mental health provider and community-based resources serving AYA patients.
- Refer patients with signs, symptoms, and a history of substance abuse or addiction to a risk reduction or substance abuse management program. Refer to smoking cessation program if needed (see [NCCN Guidelines for Smoking Cessation](#)).
- Refer patients experiencing challenges with their faith or belief in a just or fair world to faith-based resources or activities (eg, church youth groups, mentors).^{11,238}
- For those who desire to receive complementary and alternative medicine, refer them to reputable providers of these services.

Relationships

Social, Peer, and Family Relationships

AYA patients often have to endure lengthy hospital stays under the supervision of health care providers, resulting in significant isolation from their family members and peer group.²¹⁹ Isolation and alienation are common among AYA individuals diagnosed with cancer, because they often miss out on the life experiences shared by their non-ill peers. Reinforcing relationships with family, peers, and health professionals is an important aspect of life for AYA patients.^{213,239}

While some studies have identified family support and cohesiveness as important contributors to a survivor's adjustment, others have identified the important role played by same-aged peers (healthy peers as well as other AYA cancer survivors) in helping AYA patients cope with cancer and overcome feelings of loneliness.^{11,213} In one study, AYA patients with cancer (16–22 years of age) identified social support (including family members, friends, health care providers, and other patients) as their major coping strategy.²⁴⁰ In another study, some AYA patients and survivors reported that opportunities to meet other young adult survivors were more important than the support they received from family and peers.²³⁶

Peer support programs assist AYA patients and survivors in establishing and maintaining relationships with their healthy peers as well as with other AYA patients with cancer, offer opportunities to achieve age-related developmental tasks (building interpersonal and problem-solving skills), and promote positive psychosocial growth.^{236,241} Peer support also provides AYA patients with an opportunity to address areas of shared concern, such as uncertainty about the future, establishing autonomy while being increasingly dependent on family and friends, sexual identity, and infertility, thereby reducing feelings of social isolation.²⁴¹

AYA peer support groups have been developed in a variety of formats, including face-to-face meetings, camp style formats, or online support groups.^{242,243} Social networking groups focused on supporting AYA patients are particularly helpful for exchanging two primary types of support, informational and emotional, through providing advice and empathizing with other AYA patients dealing with cancer.²⁴³ Summer camps and adventure programs where participants are physically challenged have resulted in improvements in self-confidence, independence, and social contacts.^{11,242} Many of the AYA patients may not be interested in conventional cancer support groups but are willing to participate in social networking events involving other AYA patients, survivors, and family members.¹¹ Indeed, studies of AYA patients and survivors indicated that 73% of patients currently receiving therapy and 74% of off-treatment survivors reported that their needs for retreats and camp programs were unmet.^{244,245}

Communications with Health Care Professionals

Communicating information to AYA patients can be challenging, especially since there are several subgroups within the AYA population with different levels of cognitive and emotional development. It is very important to establish direct communication with the patients on an individual basis, with sufficient sensitivity to each patient's needs and preferences.²⁵ While some patients prefer not to receive direct communication about their cancer, others may desire to take a more prominent role in the management of their care. For the latter group, information should be provided directly to patients in a developmentally appropriate manner, allowing time to process the information and deliver information in a caring manner.²⁴⁶ AYA patients prefer that information about their cancer and cancer-related risks be communicated to them in a manner that is positive, respectful, and nonjudgmental.²¹⁹ In a pilot project aimed at eliciting the views of AYA

patients with cancer, humor, closely followed by expertise and knowledge, was identified as the most important characteristic that patients would like to see in their nurses.²⁴⁷ Since there is evidence that AYA patients are willing to use the internet to get health information and support, it will also be helpful to provide them with a list of recommended and reliable age-appropriate online sources to access information about their cancer, particularly with regard to treatment and late effects, fertility preservation, mental health counseling, peer support groups, diet, and nutrition.^{242,245,248} See *Online Resources for AYA Patients and Survivors* in the algorithm.

NCCN Recommendations for Supportive Care Services/Interventions for AYA Patient Relationships

- Promote communication between AYA patients and family members (parents, spouse/partners, and siblings).²⁶
- Provide information to family members and partners about psychosocial support and behavioral services to increase awareness of the possible psychosocial issues associated with diagnosis of cancer in AYAs.
- Consider family-based intervention models from pediatrics (eg, parent support groups, Impact of Traumatic Stressors Interview Schedule).¹⁷
- Establish direct communication with the individual patients, providing developmentally appropriate information about their cancer, treatment options, and potential side effects, thus reinforcing the importance of AYA involvement in decision-making.^{25,236}
- Some AYA patients prefer not to share information about their cancer with their family in an effort to shield their family members from some of the things they themselves worry about. Therefore, obtain their permission to share information with other family members and encourage completion of a HIPAA release form.

- Provide information about peer support and social networking opportunities and create flexible visiting hours and an environment that will encourage peers to visit AYA patients.²¹⁹
- Encourage completion of a medical power of attorney when appropriate.

Socioeconomic Issues

AYA patients are much more likely to be uninsured or underinsured individuals than adults or children, with many of them in a transition between their parents' insurance and their independent insurance.¹⁷ Young adult survivors of childhood cancers are more likely to report health-related unemployment, lower rates of health insurance coverage, and more difficulties obtaining coverage compared to their siblings.²⁴⁹ An analysis of 9353 AYA patients with HL showed that having either public or no health insurance was associated with poorer HL-specific survival, compared to patients with private or military insurance (HR, 2.08; 95% CI, 1.52–2.84).²⁵⁰ Furthermore, unemployment and lack of health insurance appear to be significant predictors of psychological distress in the childhood cancer survivor population.²⁵¹ Uninsured AYA patients are also less likely to participate in clinical trials.⁶⁸ As described above, advanced stage of cancer at diagnosis and lack of health insurance were significantly associated with longer time to cancer diagnosis in AYAs.⁵⁴ Greater rates of unemployment and lack of health insurance among AYA patients and survivors are also associated with limited access to long-term follow-up care.²¹² Results from the AYA HOPE study, a population-based cohort study of 523 AYA patients with cancer (15–39 years of age at diagnosis from 2007–2009), suggest that lack of health insurance is also associated with poor health-related quality of life among AYA patients with cancer.²⁵²

AYA patients with employment also experience problems in obtaining affordable health and life insurance due to their pre-existing cancer history.¹¹ Even those with relatively comprehensive insurance may be liable for substantial out-of-pocket expenses related to treatment, such as transportation costs associated with traveling for treatment, accommodations, meals, and childcare as well as expenses not related to treatment.¹¹ AYA patients who are financially independent also have to face an additional burden of loss of income because of their inability to work during treatment. Once the treatment is over, AYA patients with cancer also need long-term follow-up care for monitoring and treatment of late effects.

NCCN Recommendations For Supportive Care Services/Interventions for Socioeconomic Issues

- Assess AYA patients' health insurance status and provide information on potential sources of coverage (eg, Medicaid, Health Insurance Marketplace, parent's insurance,) and other key elements associated with insurance coverage.
- Educate AYA patients about the benefits for which they may qualify (eg, short- or long-term disability, state disability benefits, Social Security benefits, public assistance benefits).
- Provide a referral for transportation assistance programs (eg, van ride programs, voucher programs) for AYA patients who have to travel to receive treatment. Identify resources for respite care that would be helpful for those with young children.
- Integrate financial assistance for AYA cancer survivors into their survivorship plans.

Survivorship Issues

Late Effects in AYA Cancer Survivors

AYA cancer survivors are at increased risk for late effects related to cancer treatment, and the risk for long-term effects is dependent on the age at initial diagnosis and the type of treatment.²⁵³⁻²⁵⁵ In addition, the risk for many late effects may also be influenced by family history, lifestyle behaviors, and comorbid health conditions. Age at treatment exposure modifies the risk of some late effects (eg, breast cancer following chest RT, cardiomyopathy following anthracycline chemotherapy) but not others (eg, ischemic coronary artery disease following chest RT).^{256,257} Improvements in RT and surgical techniques may help reduce late effects.²⁵⁸

Much of the understanding of the long-term outcomes of AYA cancer survivors comes from the CCSS, which includes long-term survivors of childhood and adolescent cancers who were diagnosed prior to age 21.^{259,260} No such large cohort studies have addressed the survivorship issues related to cancer diagnosed in young adult patients between the ages of 22 and 39 years. Outcomes from the CCSS among those diagnosed between the ages of 15 and 20 years are particularly relevant for the NCCN Guidelines for AYA Oncology. Among adult survivors of childhood and adolescent cancer, Oeffinger et al reported that by 30 years after the cancer diagnosis, the cumulative incidence of a chronic health condition was 73%, with a cumulative incidence of 42% for severe, disabling, or life-threatening conditions or death. Importantly, the risk for a chronic health condition (ie, long-term or late effect) was similar for those diagnosed with the primary cancer in adolescence and in childhood.²⁵⁹

More recent reports have also documented the prevalence of treatment-related adverse health status and the risk of late morbidity

leading to hospitalizations among AYA cancer survivors.²⁶¹⁻²⁶⁴ In a retrospective analysis of 5-year survivors of young adult cancer ($n = 902$), the presence of at least one late morbidity leading to hospitalization was higher in survivors than in the control group (50.4% and 37.9%, respectively), and the adjusted risk of this morbidity for survivors was 1.4 times higher than for the control group.²⁶³ Other analyses of survivors of young adult cancers showed that hospitalization rates are highest for survivors of upper gastrointestinal cancer, leukemia, urologic malignancies, brain cancer, and HL.^{265,266}

A report that examined the health status of 4054 AYA cancer survivors revealed a significantly higher prevalence of current smoking (26% vs. 18%); obesity (31% vs. 27%); cardiovascular disease (14% vs. 7%); hypertension (35% vs. 29%); asthma (15% vs. 8%); disability (36% vs. 18%); and poor mental health (20% vs. 10%) and physical health (24% vs. 10%) among AYA cancer survivors compared to those who had no history of cancer.²⁶¹ In another large cohort study that included adult cancer survivors (245 patients 15–19 years of age and 12 patients 20–24 years of age at the time of diagnosis), impaired organ dysfunction (pulmonary, auditory, endocrine, and nervous system) was the most prevalent of all the adverse health outcomes.²⁶² In a report that evaluated the quality-of-life outcomes in 8375 AYA cancer survivors (diagnosed with cancer between 15–39 years) relative to the same aged controls, AYA cancer survivors were 2 times more likely to report fair or poor general health than the control group. The limitations in quality of life persisted across gender, race, ethnicity, and age.²⁶⁴

While several single cancer studies have assessed long-term outcomes among HL and testicular cancer survivors across the AYA age range, the long-term outcomes of survivors of other cancers occurring in young adulthood, such as breast, ovarian, and thyroid cancers or

melanoma, remain understudied. Since there is a paucity of literature on survivorship issues related to cancer diagnosed during adolescence and young adulthood, the findings from the CCSS and similar studies focusing on childhood and adolescent cancer survivors could be extrapolated to the survivors of AYA cancers, albeit with caution. Increased adherence to long-term follow-up guidelines may contribute to improvement in health status of AYA cancer survivors.²⁶¹

Some of the more common late effects among AYA cancer survivors are discussed below.

Secondary Cancers

AYA cancer survivors (between 15–39 years of age at the time of diagnosis) are at significant risk of developing a variety of secondary cancers compared to the general population,^{267,268} as well as survivors of cancer diagnosed during either childhood or older adulthood.²⁶⁹ Though secondary cancers may be caused by a hereditary syndrome, they are thought to be largely caused by treatment exposure.²⁵⁸ The risk and specific types of secondary cancers are widely dependent on the type of initial cancer diagnosis and treatment exposure,²⁷⁰⁻²⁷² though the most common secondary malignancies are breast cancer, gastrointestinal cancer, genital cancers, and melanoma.²⁶⁹ RT exposure is particularly associated with risk of secondary cancers.^{268,269}

AYA survivors of HL diagnosed between 21 to 39 years of age are at increased risk of developing secondary cancers.²⁷¹ The most frequently observed secondary cancers are breast, lung, thyroid, and gastrointestinal cancers.²⁵⁶ AYA women with HL treated with chest RT are at significantly increased risk of developing secondary breast cancer, and the risk for secondary breast cancer among HL survivors is strongly associated with age at diagnosis and mediastinal RT dose.^{80,273-275} In a cohort of 770 female survivors who had been

diagnosed with HL before age 41 years, the risk of developing breast cancer increased with increasing RT dose (38.5 Gy or more).²⁷³ In an international, population-based study of 3817 female survivors of HL diagnosed at age 30 years or younger, Travis et al reported that for women treated at age 25 years with a chest RT dose of at least 40 Gy without alkylating agents, the estimated cumulative absolute risks of developing breast cancer by age 35, 45, and 55 years were 1.4%, 11.1%, and 29.0%, respectively.²⁷⁴

Alkylating agent-based chemotherapy for HL has been associated with a modestly increased risk for secondary lung cancers in patients diagnosed at 40 years or younger, and the risk increased with both increasing number of cycles of alkylating agents and the cumulative dose.²⁷⁶ In this study, the risk of secondary lung cancer was substantially higher among survivors who smoked (9.6% due to treatment alone compared to 63.3% due to the combination of treatment and smoking). In a collaborative British cohort study that assessed the risk of developing secondary cancers in 5798 patients diagnosed with HL between 15 and 34 years of age, the 20-year cumulative risk of second cancer was 13% and 18%, respectively, for chemotherapy alone and combined modality therapy.²⁷⁷ Risks for secondary lung cancer, NHL, and leukemia were significantly higher after treatment with chemotherapy alone, whereas combined modality therapy was associated with a higher risk for these and several other cancers.²⁷⁷

AYA survivors of testicular cancer are also at significantly increased risk of developing secondary cancers, including contralateral testicular cancer, leukemia, malignant mesothelioma, and cancers of the lung, colon, esophagus, stomach, and pancreas.^{278,279} In a population-based study of 29,515 testicular cancer survivors, the 15-year cumulative risk of developing contralateral testicular cancer was almost 2%, which is

12-fold higher than that of the general population.²⁸⁰ In an international, population-based study of 40,576 testicular cancer survivors, the cumulative risk of developing solid tumors by age 75 years was slightly higher for patients with seminomas than for patients without seminomas who were diagnosed at 35 years of age (36% and 31%, respectively).²⁸¹ The combination of chemotherapy and RT was associated with a larger risk of secondary solid tumors than RT alone, although the difference was not statistically significant.²⁸¹ Secondary leukemia related to chemotherapy with topoisomerase II inhibitors and alkylating agents has also been reported in testicular cancer survivors. In one study, the cumulative incidence of secondary AML was 0.5% at 2 years after treatment with high-dose chemotherapy (with a median cumulative etoposide dose of 4.9 g/m²) and autologous HSCT.²⁸² In another study involving 42,722 one-year survivors of testicular cancer, the estimated excess cumulative leukemia risk was 0.23% at 30 years after testicular cancer diagnosis.²⁸³ The risk for secondary AML was higher for patients treated with chemotherapy compared to those treated with radiotherapy alone.

The risk for secondary malignancies among survivors of cervical and breast cancers, NHL, and melanoma has been assessed in only a few cohort studies.²⁸⁴⁻²⁸⁶ Among 104,760 one-year survivors of cervical cancer, patients heavily treated with RT were at increased risk for secondary cancers at sites in close proximity to the cervix beyond 40 years of follow-up. The 40-year cumulative risk for any second cancer was higher among women diagnosed before 50 years of age than among women diagnosed after 50 years of age (22.2% and 16.4%, respectively).²⁸⁴ In a population-based cohort of 376,825 one-year survivors of breast cancer from the Scandinavian cancer registries, women diagnosed at 40 years or younger with localized disease were particularly at risk of developing a second cancer at 30 or more years

after breast cancer diagnosis.²⁸⁵ In an analysis of 28,131 patients from the Swedish Cancer Registry, the risk of developing subsequent solid tumors after NHL during the first decade was higher among patients diagnosed between 20 and 39 years of age compared to those who were age 40 years or older at the time of diagnosis.²⁸⁶ In the SEER database analysis of 89,515 melanoma survivors, patients diagnosed at younger than 30 years of age had the highest risk of developing secondary cancers (breast, prostate, and NHL being the most common cancers) at more than 20 years after initial diagnosis. HSCT and RT to head and neck also increased the risk of subsequent cancers in the oral cavity.²⁸⁷

Long-term AYA survivors of pediatric-predominant cancers, including ALL, AML, CNS tumors, and bone and soft tissue sarcomas, are also at risk of developing secondary cancers. Among the survivors of ALL and AML, CNS was the most common secondary cancer (24%) followed by thyroid cancer (22%). For patients who survived for at least 5 years after the diagnosis, the cumulative incidences of secondary cancers at 30 years was 3.9% and 4.3%, respectively, for ALL and AML.²⁸⁸

The risk is especially higher among patients diagnosed at a younger age (17 years or younger for ALL and CNS tumors; 18 years or younger for bone and soft tissue sarcomas).²⁶⁷ Among long-term survivors of bone cancers at 25 years after diagnosis, the cumulative incidence of subsequent cancers is higher for those diagnosed with Ewing sarcoma compared to those diagnosed with osteosarcoma (9.0% and 5.4%, respectively).^{289,290}

Clinicians who provide care for AYA cancer survivors must implement and evaluate methods for improving awareness of secondary cancers. They must also implement appropriate surveillance strategies for early detection of these malignancies.²⁹¹ An annual mammogram and breast

MRI are recommended for women treated with a chest RT ≥ 20 Gy prior to 30 years of age. Women treated with chest RT between 10 and 20 Gy may participate in shared decision-making with their physician about screening.²⁹² A colonoscopy is recommended starting at age 35 years or 10 years after completion of RT, whichever occurs last, for patients treated with abdominal or pelvic RT ≥ 30 Gy. Routine endocrine, ophthalmology, and dental evaluation (dental exam and cleaning every 6 months) is recommended for long-term AYA cancer survivors treated with chemotherapy and/or RT and those treated with TBI for HSCT.²⁸⁷ Screening for secondary AML or myelodysplasia should be done by assessing complete blood count (CBC) and bone marrow exam as clinically indicated based on symptoms.

Cardiovascular Complications

Cardiovascular complications (congestive heart failure [CHF], myocardial infarction [MI], pericardial disease, and valvular abnormalities) are the leading non-malignant cause of death among survivors of AYA cancers, compared to the general population.²⁹³⁻²⁹⁶ A retrospective cohort study comparing 5673 two-year AYA survivors of cancer to 57,617 controls showed that the cancer survivors were more likely to develop cardiovascular disease (adjusted incidence rate ratio, 2.37; 95% CI, 1.93–2.93), with risk being highest among survivors of breast cancer (adjusted incidence rate ratio, 3.63; 95% CI, 2.41–5.47) and leukemia (adjusted incidence rate ratio, 4.23; 95% CI, 1.73–10.31).²⁹⁷ A systematic review and meta-analysis of 64 studies of specific cardiovascular late effects in 143,606 survivors of childhood or adolescent cancer reported that the weighted average prevalence was 19.7% for hypertension and 2.3% for stroke in this population.²⁹⁸

Mediastinal RT and anthracycline-based chemotherapy are the strongest risk factors for late cardiovascular complications in AYA survivors of HL.^{257,299,300} In the British cohort study of 7033 patients with



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

HL, the risk of death from MI was highest for patients younger than 35 years at the time of treatment with supradiaphragmatic RT.³⁰⁰ Patients treated with anthracyclines were at increased risk for MI within one year after first treatment, whereas the risk for MI among patients treated with supradiaphragmatic RT and vincristine without anthracyclines increased sharply after the first year of follow-up.³⁰⁰ In another study of 1474 survivors of HL younger than 41 years at the time of treatment, mediastinal RT increased the risk of MI, CHF, and valvular disorders, whereas the addition of anthracyclines to RT elevated the risks for CHF and valvular disorders.²⁵⁷ The 25-year cumulative incidence of CHF after mediastinal RT and anthracyclines was 8%. An analysis of 15,815 survivors of childhood cancer, including participants from the CCSS ($n = 12,407$), showed that the anthracycline daunorubicin may be less cardiotoxic than doxorubicin (HR, 0.45; 95% CI, 0.23–0.73).³⁰¹ Several studies, including randomized controlled trials and systematic reviews, have supported the use of dexrazoxane as a cardioprotectant for children, adolescents, and adults treated with anthracycline chemotherapy.^{302–304} Therefore, the addition of a cardioprotectant such as dexrazoxane is recommended for AYA patients receiving an anthracycline.

Cisplatin-based chemotherapy is associated with long-term risk for cardiovascular complications in testicular cancer survivors.^{305,306 307} In a Dutch study of 2,512 testicular cancer survivors, nonseminoma testicular cancer survivors younger than 30 years at diagnosis treated with mediastinal RT and chemotherapy with cisplatin, vinblastine, and bleomycin were at increased risk for MI within 20 years of treatment.³⁰⁵ Hagnès et al reported that treatment with cisplatin, bleomycin, and etoposide and/or RT was associated with increased risks for cardiovascular disease in testicular cancer survivors; chemotherapy alone or in combination with RT significantly increased the risk for MI.³⁰⁶

Survivors of brain tumors, leukemia, NHL, and bone and soft tissue sarcomas treated with anthracyclines and cardiac irradiation are also at significantly higher risk of adverse cardiovascular complications. However, the majority of patients included in these studies were younger than 21 years at the time of diagnosis.³⁰⁸ More recent reports have also documented increased cardiovascular complications among survivors of lymphoma, brain tumor, leukemia, and testicular cancer.^{294,309}

Pulmonary Complications

Analysis of data from the CCSS showed that pulmonary complications (eg, asthma, chronic cough, emphysema, lung fibrosis) are more frequent in survivors ($n = 20,690$) than in sibling controls ($n = 4,027$).³¹⁰ Chemotherapy, chest RT, and craniospinal irradiation are associated with pulmonary toxicity and can compromise pulmonary function in AYA cancer survivors.^{307,311,312}

Age at diagnosis (15–21 years compared with age younger than 15 years) and pulmonary toxic chemotherapy alone or combined with chest RT were associated with a significantly increased relative risk of lung fibrosis and pleurisy.³¹¹ The cumulative incidence increased up to 15 to 20 years after diagnosis. Other complications include recurrent pneumonia, chronic cough, supplemental oxygen use, and shortness of breath.

A large international study reported a significant increase in mortality from respiratory diseases among testicular cancer survivors treated with chemotherapy compared to the general population.³¹³ Risk factors for pulmonary toxicity include age at diagnosis, cumulative bleomycin dose, reduced glomerular filtration rate, renal dysfunction, and stage IV disease at presentation.³¹⁴ Hagnès et al reported that among 1049 testicular cancer survivors, those treated with chemotherapy combined

with pulmonary surgery or large cumulative cisplatin doses had significantly reduced pulmonary function compared with those treated with surgery alone.³¹⁵ Bleomycin dose was not associated with restrictive lung disease. Instead, in a multivariate model, cisplatin dose ($P = .007$) and age at diagnosis ($P = .008$) were associated with the risk for restrictive lung disease.

Neurologic Complications

AYA survivors of brain tumors treated with cranial RT are at increased risk for neurologic complications, including hearing impairments, cataracts and other vision problems, seizure disorders, and coordination and motor control problems.³¹⁶⁻³¹⁹ However, these findings are relevant to survivors diagnosed at 21 years of age or younger.

Long-term AYA survivors of testicular cancer who were treated with cisplatin-based chemotherapy are at risk for neurologic complications such as sensory neuropathy, tinnitus, hearing impairment, and Raynaud's phenomena (blue or cold hands or feet on cold exposure).³⁰⁷ Among 1814 survivors of testicular cancer included in a Norwegian observational study, Raynaud-like phenomena were the most frequently reported complications (39% of men), followed by paresthesia of the hands or feet (29%), and tinnitus and hearing impairment (22% and 21%, respectively) by men treated with chemotherapy compared to those not treated with chemotherapy.³²⁰ The incidences of paresthesia of the feet were also higher among men treated with RT.

Patients treated with vincristine, docetaxel, or paclitaxel are also at risk for long-term peripheral neuropathy.³²¹ A cross-sectional study of 80 ALL survivors who had been treated with vincristine within the past 3 years found that 33.75% had neuropathy as measured electrophysiologically, although the study did report significant

improvement over time.³²² Another study of 37 ALL survivors who had been treated with vincristine at least 2 years before reported that 29.7% of patients showed abnormalities in nerve conduction studies.³²³ A study of 605 breast cancer survivors at least 2 years out from diagnosis reported that survivors treated with docetaxel or paclitaxel were more likely to experience peripheral neuropathy (31% for docetaxel, 44% for paclitaxel) than those who were not treated with these chemotherapies (17% for no chemotherapy, 20% for other chemotherapies).³²⁴

Stroke, although relatively uncommon, is a devastating neurologic complication in AYA survivors of brain tumors and leukemia treated with cranial RT and survivors of HL treated with mantle field RT.³²⁵⁻³²⁷ In a retrospective cohort study of 5-year survivors of HL ($N = 2,201$), those treated with RT to the neck and mediastinum were particularly at increased risk for stroke and transient ischemic attack.³²⁸ The incidences were higher among patients diagnosed at younger than 21 years than those diagnosed between 21 and 30 years of age. The standardized incidence ratio was 3.8 and 3.1, respectively. In an analysis of CCSS data, out of 271 survivors who reported a stroke, 26% reported a second stroke.³²⁷ Predictors of recurrent stroke include history of brain tumor, exposure to cranial RT (total dose ≥ 50 Gy), older age at first stroke, and hypertension.³²⁷

Nephrotoxicity

Long-term renal dysfunction has been reported in survivors of testicular cancer treated with infradiaphragmatic RT and cisplatin-based chemotherapy. In one study with a long-term follow-up, renal impairment was observed in 8% of patients treated with abdominal RT alone compared to a 14% reduction in patients with chemotherapy with or without RT. Age at treatment and type of treatment were associated with impaired renal function.

Bladder and Bowel Incontinence

Cancer survivors treated with pelvic RT are more likely to experience bladder and bowel incontinence than those who were not treated with pelvic RT. A study of 104 survivors of cervical or endometrial cancer found that the severity of bladder and bowel symptoms were significantly associated with pelvic RT treatment.³²⁹ Two studies of long-term gynecologic cancer survivors ($N = 77$ and $N = 519$) found that approximately 12% to 17% of survivors treated with pelvic RT develop symptoms of bowel incontinence.^{330,331} Bowel incontinence was associated with the mean radiation dose, with the larger study reporting that mean doses >50 Gy carry the greatest risk.³³⁰ Cancer survivors who experienced bladder and/or bowel incontinence as a result of pelvic RT therapy have reported considerable distress and a decreased quality of life as a result of their symptoms.^{329,332}

Endocrine Complications

Cranial or spinal RT, TBI, and targeted RT to the neck, abdomen, pelvis, and testes are associated with endocrine late effects in survivors of AYA cancers.¹²¹ The most common endocrine complications include growth hormone (GH) deficiency, thyroid gland abnormalities, gonadal dysfunction, obesity, diabetes mellitus, and decreased fertility.^{76,110,333} AYA cancer survivors treated with an RT dose of ≥ 18 Gy to the hypothalamic-pituitary-adrenal (HPA) axis are at high risk for GH deficiency, whereas those treated with an RT dose of ≥ 40 Gy to the HPA axis are at risk of developing central hypothyroidism, gonadotropin deficiency, and central adrenal insufficiency.

GH deficiency can be observed within 5 years after treatment with RT doses higher than 30 Gy, whereas in patients treated with lower doses (18–24 Gy) it may not be evident for 10 years or more.¹²¹ Secondary thyroid cancers, hypothyroidism, and, to a lesser extent, hyperthyroidism are more common among AYA survivors of brain

tumors, ALL, HL, and those who have undergone HSCT.^{316,334,335}

Testicular cancer survivors treated with chemotherapy and RT are at greater risk for hypogonadism.³⁰⁷ Low testosterone levels and testosterone replacement have been reported in 34% and 4% of testicular cancer survivors, respectively.³³⁶ Risk of endocrine complications may increase over time, indicating a need for lifelong evaluation.^{333,337}

Long-term Follow-up

As discussed above, AYA cancer survivors have a high risk of developing a wide range of late effects. AYA cancer survivors may benefit from regular screening and early intervention for cardiovascular disease.³³⁸ Continued follow-up of AYA cancer survivors is needed to monitor the pulmonary complications.³³⁹ Development of a “Cancer Treatment Summary and Survivorship Care Plan,” including periodic evaluation with focused history, physical examination, and screening based on treatment exposures, and risk for treatment-related late effects, should be an integral part of management of AYA cancer survivors.^{254,340,341} Issues related to insurance, clinical team composition (presence of a provider knowledgeable in childhood cancer), scheduling (availability of flexible scheduling), and comprehensive nature of the care provided were identified as patient-perceived facilitators for the transition of survivorship care in young adult survivors of childhood cancer.³⁴²

The models for AYA survivorship care include cancer center follow-up (primary treatment team or specialized long-term follow-up clinics), follow-up by the patient’s primary care physician, or a combination of both (shared care model).^{341,343} Some studies have shown that a shared care model involving both the primary oncology team and the primary

care physician is feasible and can facilitate appropriate care in childhood cancer survivors.³⁴⁴⁻³⁴⁶

Risk stratification of survivors based on the current medical issues and prior treatments may be helpful to determine the different levels of follow-up in the shared care model.^{343,347,348} Survivors at low risk for late effects (treated with surgery alone and/or chemotherapy with no RT, not including alkylating agents, anthracycline, bleomycin, or epipodophyllotoxin) can be transitioned to their primary care physician soon after completion of therapy. Survivors at moderate risk for late effects (treated with low- or moderate-dose chemotherapy with no RT, chemotherapy-containing alkylating agents, anthracycline, bleomycin, or epipodophyllotoxin) can be evaluated by their oncology team or primary care physician on alternating years. Survivors at high risk for late effects, such as those treated for CNS cancers or those treated with HSCT, any RT, high-dose alkylating agents, anthracycline, bleomycin, or epipodophyllotoxin, should be followed annually by their oncology team and continue follow-up care with their primary care physician.

The screening recommendations included in the NCCN Guidelines for AYA Oncology are adapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, available at survivorshipguidelines.org.²⁹¹ See *Screening Recommendations for AYA Survivors* in the algorithm for specific recommendations based on the treatment exposure and timing and intensity of screening. These recommendations may be adapted based on additional risk factors.

Palliative and End-of-life Care

Palliative care is interdisciplinary care of patients with life-threatening illnesses, malignant as well as non-malignant. The goal of palliative

care in patients with cancer is to control symptoms, relieve emotional and physical suffering from adverse effects of treatment, and improve quality of life for patients and their families, regardless of the stage of the disease or the need for other therapies.^{349,350} See the [NCCN Guidelines for Palliative Care](#).

Palliative care services for AYA patients should be provided by a multidisciplinary team with expertise in understanding the psychosocial, emotional, developmental, and financial issues that are unique to this age group.^{349,351} Introduction of palliative care for symptom management and psychosocial support should occur before the patient's condition is considered "palliative" in order to provide the best possible care.³⁵² Palliative care is appropriate even when patients are being treated with curative intent, and there is growing consensus that AYA patients should have access to palliative care services from the time of diagnosis until the time of death or cure.³⁵² Patients, caregivers, and health care professionals should be taught that palliative care is an integral part of their comprehensive cancer care.³⁵¹ AYA patients usually do not make decisions in isolation. While some AYA patients have the ability to make life and death decisions independently, many are either not the primary decision maker or they rely intensely on input from parents, spouses, significant others, and other family members.³⁴⁹ Palliative care services should also consider the psychosocial needs of the patient's family, friends, and caregivers.³⁵² Patients' goals, dreams, and desires to leave a legacy are important considerations to address.³⁵¹

End-of-life care involves the palliation of symptoms, management of delirium, existential distress, discussion about the place of death, and support of family.^{349,351} It is imperative for health care professionals not to assume that AYA patients may be less inclined to discuss death and other end-of-life issues.³⁴⁹ In an exploratory study of 50 adolescent

patients (15–21 years of age) with and without chronic illnesses, adolescents were willing to discuss end-of-life decision-making by taking part in a one-on-one survey administered by a researcher.³⁵³ The quality of life of AYA patients should be heeded by the care team.³⁵¹ During palliative and end-of-life care, AYA patients may be able to and wish to continue to engage in their day-to-day activities, even if some activities are in discord with medical advice (eg, participating in strenuous physical activity).

Discussion about end-of-life preferences should begin at the time of initiating treatment, but details should be individualized according to the preferences of the AYA patient and family.³⁵⁴ A chart review regarding end-of-life care in 663 AYA patients showed that these patients receive medically intensive therapy at about the same rates as older patients, indicating a need for better understanding of care preferences in these patients.³⁵⁵ AYA patients' opinions about end-of-life care vary across this age group. Exploring individual preferences for end-of-life care and providing interventions specific to the needs of this patient population could significantly improve end-of-life care.^{354,356} In one retrospective review, a significant number of adolescents dying of cancer felt that discussions about end of life occurred very close to death, allowing very little time to psychologically prepare for death.³⁵⁷ Physicians with expertise in end-of-life care should facilitate discussion of difficult issues such as nutrition/hydration, sedation, treatment cessation, and place of death.³⁴⁹ An advance care planning document is recommended for terminally ill AYA patients with metastatic cancer.^{354,358} Ongoing psychosocial support is extremely important during the transition to end-of-life care.

Summary

AYA patients with cancer should be recognized as a distinct population that has unique medical and psychosocial needs. It is important for physicians to identify issues specific to the AYA population and recommend appropriate interventions with the aim of improving clinical outcomes. Most importantly, all AYA patients should have access to age-appropriate supportive care as well as medical subspecialty services appropriate for their cancer diagnosis.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

Table 1. Age-specific SEER Incidences of Cancer by Cancer Site and Sex in the AYA Population (2010–2014)^{a,b}

Cancer type	Ages 15–39 (Females)
Carcinoma of breast	21.0
Thyroid carcinoma	18.3
Carcinoma of cervix and uterus	8.9
Melanoma	8.5
Carcinoma of colon and rectum	4.0
HL	3.4
NHL	3.2
Leukemias	2.9
CNS cancers	2.5
Soft tissue sarcomas	2.3
Carcinoma of the kidney	1.7
Carcinoma of head and neck	1.4
Germ cell neoplasms	1.0

Cancer type	Ages 15–39 (Males)
Germ cell neoplasms	11.2
Melanoma	5.0
NHL	4.7
Carcinoma of colon and rectum	4.2
Leukemias	3.9
Thyroid carcinoma	3.9
HL	3.5
Soft tissue sarcomas	3.2
CNS cancers	3.3
Carcinoma of the kidney	2.4
Carcinoma of head and neck	1.7
Bone sarcomas	1.1

a. These are incidence rates are per 100,000.

b. Data from Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER website, April 2017.

References

1. Bleyer A, O'Leary M, Barr R, Ries L. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767 2006. Available at: <http://www.seer.cancer.gov/publications/aya/>.
2. Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer 2016;122:1009-1016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26848927>.
3. Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 2007;110:2385-2393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17918260>.
4. Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer 2008;50:1101-1104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18360838>.
5. Tai E, Beaupin L, Bleyer A. Clinical trial enrollment among adolescents with cancer: supplement overview. Pediatrics 2014;133 Suppl 3:S85-90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24918212>.
6. Smith AW, Seibel NL, Lewis DR, et al. Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer 2016;122:988-999. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26849003>.
7. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006;107:1645-1655. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16906507>.
8. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin 2007;57:242-255. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17626120>.
9. Abrams AN, Hazen EP, Penson RT. Psychosocial issues in adolescents with cancer. Cancer Treat Rev 2007;33:622-630. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17434265>.
10. Zebrack BJ, Block R, Hayes-Lattin B, et al. Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients. Cancer 2013;119:201-214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22744865>.
11. Zebrack BJ. Psychological, social, and behavioral issues for young adults with cancer. Cancer 2011;117:2289-2294. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523748>.
12. Zebrack B, Butler M. Context for understanding psychosocial outcomes and behavior among adolescents and young adults with cancer. J Natl Compr Canc Netw 2012;10:1151-1156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22956811>.
13. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-298. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18354417>.
14. Tricoli JV, Blair DG, Anders CK, et al. Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer 2016;122:1017-1028. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26849082>.
15. Ramphal R, Meyer R, Schacter B, et al. Active therapy and models of care for adolescents and young adults with cancer. Cancer 2011;117:2316-2322. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523752>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

16. Nass SJ, Beaupin LK, Demark-Wahnefried W, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. *Oncologist* 2015;20:186-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25568146>.

17. Closing the gap: Research and care imperatives for adolescents and young adults with cancer: Report of the adolescent and young adult oncology progress review group: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Livestrong™ Young Adult Alliance 2006. Available at: <https://www.cancer.gov/types/aya/research/ayao-august-2006.pdf>.

18. Trama A, Botta L, Foschi R, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. *Lancet Oncol* 2016;17:896-906. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27237614>.

19. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:4148-4154. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23091096>.

20. Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. *Cancer* 2010;116:1964-1973. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20151425>.

21. Verma V, Denniston KA, Lin CJ, Lin C. A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors. *Front Oncol* 2017;7:82. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28534008>.

22. Tai E, Buchanan N, Westervelt L, et al. Treatment setting, clinical trial enrollment, and subsequent outcomes among adolescents with cancer: a literature review. *Pediatrics* 2014;133 Suppl 3:S91-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24918213>.

23. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. *Oncologist* 2006;11:590-601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16794238>.

24. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* 2014;64:83-103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24488779>.

25. Ferrari A, Thomas D, Franklin AR, et al. Starting an adolescent and young adult program: some success stories and some obstacles to overcome. *J Clin Oncol* 2010;28:4850-4857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20479411>.

26. Zebrack B, Mathews-Bradshaw B, Siegel S. Quality cancer care for adolescents and young adults: a position statement. *J Clin Oncol* 2010;28:4862-4867. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20855821>.

27. Alvarez E, Keegan T, Johnston EE, et al. Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers. *Cancer* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28241089>.

28. U.S. National Library of Medicine Key MEDLINE® Indicators Available at: http://www.nlm.nih.gov/bsd/bsd_key.html.

29. Alman BA, Pajerski ME, Diaz-Cano S, et al. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. *Diagn Mol Pathol* 1997;6:98-101. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9098648>.

30. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P. Sarcomas in TP53 germline mutation carriers. *Cancer* 2012;118:1387-1396. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21837677>.

31. Abramson DH, Ellsworth RM, Kitchin FD, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

induced? Ophthalmology 1984;91:1351-1355. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/6595610>.

32. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/1978757>.

33. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011;35:1712-1721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21997692>.

34. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314-318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21173220>.

35. Friedman JM. Neurofibromatosis 1. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, WA. ; 2009: Initial Posting: October 2, 1998; Last Update: June 1992, 2009.

36. Larsson C, Skogseid B, Oberg K, et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-87. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/2894610>.

37. Minoletti F, Butti MG, Coronelli S, et al. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 1994;11:51-57. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/7529046>.

38. Gaztambide S, Vazquez F, Castano L. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva Endocrinol 2013;38:17-28. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23435440>.

39. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011;13:755-764. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21552134>.

40. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-1783. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/14652239>.

41. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46:S20-26. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20307840>.

42. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21969503>.

43. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23297039>.

44. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-1585. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/22029979>.

45. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22075171>.

46. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV

vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23873171>.

47. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63:1-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25167164>.

48. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016;65:1405-1408. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27977643>.

49. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60:99-9119. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20228384>.

50. Bryant H. Screening for cancer in children, adolescents, and young adults: questions-and more questions. Cancer 2011;117:2275-2280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523746>.

51. Pollock BH, Krischer JP, Vietti TJ. Interval between symptom onset and diagnosis of pediatric solid tumors. J Pediatr 1991;119:725-732. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1941378>.

52. Klein-Geltink J, Pogany L, Mery LS, et al. Impact of age and diagnosis on waiting times between important healthcare events among children 0 to 19 years cared for in pediatric units: the Canadian Childhood Cancer Surveillance and Control Program. J Pediatr Hematol Oncol 2006;28:433-439. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16825989>.

53. Dang-Tan T, Trottier H, Mery LS, et al. Delays in diagnosis and treatment among children and adolescents with cancer in Canada.

Pediatr Blood Cancer 2008;51:468-474. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18454472>.

54. Martin S, Ulrich C, Munsell M, et al. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 2007;12:816-824. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17673613>.

55. Boissel N, Auclerc M-F, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003;21:774-780. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12610173>.

56. Ribera J-M, Oriol A, Sanz M-A, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008;26:1843-1849. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18398150>.

57. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646-1654. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18502832>.

58. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-918. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19124805>.

59. Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 2003;98:571-580. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12879475>.

60. Scurr M, Judson I. How to treat the Ewing's family of sarcomas in adult patients. *Oncologist* 2006;11:65-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16401715>.

61. Tai E, Pollack LA, Townsend J, et al. Differences in non-Hodgkin lymphoma survival between young adults and children. *Arch Pediatr Adolesc Med* 2010;164:218-224. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20194253>.

62. Sandlund JT. Should adolescents with NHL be treated as old children or young adults? *Hematology Am Soc Hematol Educ Program* 2007:297-303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18024643>.

63. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. *Leukemia* 2011;25:153-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21030984>.

64. Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. *Med Pediatr Oncol* 2002;38:1-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11835231>.

65. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. *J Adolesc Health* 1997;21:366-373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9401854>.

66. Shochat SJ, Fremgen AM, Murphy SB, et al. Childhood cancer: patterns of protocol participation in a national survey. *CA Cancer J Clin* 2001;51:119-130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11577480>.

67. Downs-Canner S, Shaw PH. A comparison of clinical trial enrollment between adolescent and young adult (AYA) oncology patients treated at affiliated adult and pediatric oncology centers. *J*

Pediatr Hematol Oncol 2009;31:927-929. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19855302>.

68. Parsons HM, Harlan LC, Seibel NL, et al. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? *J Clin Oncol* 2011;29:4045-4053. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21931022>.

69. Howell DL, Ward KC, Austin HD, et al. Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. *J Clin Oncol* 2007;25:4610-4615. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17925556>.

70. Albritton KH, Wiggins CH, Nelson HE, Weeks JC. Site of oncologic specialty care for older adolescents in Utah. *J Clin Oncol* 2007;25:4616-4621. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17925557>.

71. Bleyer A. The Quid Pro Quo of pediatric versus adult services for older adolescent cancer patients. *Pediatr Blood Cancer* 2010;54:238-241. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19813248>.

72. Gupta AA, Edelstein K, Albert-Green A, D'Agostino N. Assessing information and service needs of young adults with cancer at a single institution: the importance of information on cancer diagnosis, fertility preservation, diet, and exercise. *Support Care Cancer* 2013;21:2477-2484. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23604520>.

73. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. *Leukemia* 2015;29:526-534. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25079173>.

74. Gerber NK, Wexler LH, Singer S, et al. Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. *Int J*

Radiat Oncol Biol Phys 2013;86:58-63. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/23414767>.

75. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010;28:4790-4799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20439647>.

76. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med 2004;2:61-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15053285>.

77. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004;54:208-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15253918>.

78. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010;174:840-850. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21128808>.

79. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831-4841. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20458029>.

80. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-475. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12876089>.

81. Janson C, Leisenring W, Cox C, et al. Predictors of marriage and divorce in adult survivors of childhood cancers: a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2009;18:2626-2635. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19815636>.

82. Bleyer A, Choi M, Wang SJ, et al. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009;53:1205-1210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19821538>.

83. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer 2011;19:1533-1538. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20803345>.

84. Figueroa-Moseley C, Jean-Pierre P, Roscoe JA, et al. Behavioral interventions in treating anticipatory nausea and vomiting. J Natl Compr Canc Netw 2007;5:44-50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17239325>.

85. Huang TT, Hudson MM, Stokes DC, et al. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest 2011;140:881-901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21415131>.

86. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-760. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2715805>.

87. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000;82:1636-1645. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10817497>.

88. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005;23:8588-8596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16314621>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

89. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. *Cancer* 2009;115:23-35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19072983>.

90. Armenian SH, Sun CL, Kawashima T, et al. Long-term health-related outcomes in survivors of childhood cancer treated with hematopoietic cell transplantation (HCT) versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). *Blood* 2011;118:1413-1420. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21652685>.

91. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. *J Clin Oncol* 2011;29:2230-2239. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21464398>.

92. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. *Blood* 2011;117:3214-3219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263156>.

93. Zecca M, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. *Blood* 2002;100:1192-1200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12149197>.

94. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. *N Engl J Med* 2012;367:1487-1496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23075175>.

95. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. *Blood* 2006;108:2867-2873. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16788100>.

96. Inaba H, Yang J, Kaste SC, et al. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. *J Clin Oncol* 2012;30:3991-3997. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23032628>.

97. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood* 2009;113:1175-1183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18971419>.

98. Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. *J Clin Oncol* 2010;28:4800-4809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20212260>.

99. Kondryn HJ, Edmondson CL, Hill J, Eden TO. Treatment non-adherence in teenage and young adult patients with cancer. *Lancet Oncol* 2011;12:100-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20580606>.

100. Windebank KP, Spinetta JJ. Do as I say or die: compliance in adolescents with cancer. *Pediatr Blood Cancer* 2008;50:1099-1100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18360837>.

101. Kato PM, Cole SW, Bradlyn AS, Pollock BH. A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. *Pediatrics* 2008;122:e305-317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18676516>.

102. Rosenberg AR, Macpherson CF, Kroon L, Johnson R. Rethinking adherence: a proposal for a new approach to risk assessment. *J Adolesc Young Adult Oncol* 2013;2:83-86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23781406>.

103. Kahana S, Drotar D, Frazier T. Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. *J Pediatr Psychol* 2008;33:590-611. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18192300>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

104. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group. J Clin Oncol 2012;30:3408-3416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22649147>.

105. Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013;31:1239-1247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23382474>.

106. Gunnes MW, Lie RT, Bjorge T, et al. Reproduction and marriage among male survivors of cancer in childhood, adolescence and young adulthood: a national cohort study. Br J Cancer 2016;114:348-356. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26794280>.

107. Chow EJ, Stratton KL, Leisenring WM, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2016;17:567-576. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27020005>.

108. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-218. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15811616>.

109. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006;91:1723-1728. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16492690>.

110. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 2009;5:88-99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19165221>.

111. Green DM, Sklar CA, Boice JD, Jr., et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from

the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-2381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19364956>.

112. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010;28:332-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19949008>.

113. Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2013;14:873-881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23856401>.

114. van Dorp W, Mulder RL, Kremer LC, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. J Clin Oncol 2016;34:3440-3450. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27458300>.

115. Haukvik UKH, Dieset I, Bjoro T, et al. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006;17:1428-1433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16831852>.

116. van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol 2012;30:291-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22184372>.

117. Bramswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol

2015;16:667-675. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/25959806>.

118. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol* 1996;14:1718-1729. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/8622093>.

119. Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. *J Clin Oncol* 1999;17:2365-2370. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/10561298>.

120. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. *Blood* 2008;111:101-108. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17890454>.

121. Chemaitilly W, Sklar CA. Endocrine complications in long-term survivors of childhood cancers. *Endocr Relat Cancer* 2010;17:R141-159. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20453080>.

122. Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. *Fertil Steril* 2013;100:1180-1186. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24012199>.

123. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. *Ann Oncol* 2008;19:1795-1801. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18544558>.

124. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. *J Natl Cancer Inst Monogr* 2005:12-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15784814>.

125. Meistrich ML, Wilson G, Brown BW, et al. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue

sarcomas. *Cancer* 1992;70:2703-2712. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/1423201>.

126. Pryzant RM, Meistrich ML, Wilson G, et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. *J Clin Oncol* 1993;11:239-247. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/8426200>.

127. Matos E, Skrbinc B, Zakotnik B. Fertility in patients treated for testicular cancer. *J Cancer Surviv* 2010;4:274-278. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20602187>.

128. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. *Cancer* 2011;117:2301-2310. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523750>.

129. Redig AJ, Brannigan R, Stryker SJ, et al. Incorporating fertility preservation into the care of young oncology patients. *Cancer* 2011;117:4-10. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21235031>.

130. Fernbach A, Lockart B, Armus CL, et al. Evidence-based recommendations for fertility preservation options for inclusion in treatment protocols for pediatric and adolescent patients diagnosed with cancer. *J Pediatr Oncol Nurs* 2014;31:211-222. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24799444>.

131. Benedict C, Thom B, D NF, et al. Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation. *Cancer* 2016;122:2101-2109. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27213483>.

132. Waks AG, Partridge AH. Fertility preservation in patients with breast cancer: necessity, methods, and safety. *J Natl Compr Canc Netw* 2016;14:355-363. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26957619>.

133. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23715580>.

134. Johnson RH, Kroon L. Optimizing fertility preservation practices for adolescent and young adult cancer patients. J Natl Compr Canc Netw 2013;11:71-77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23307983>.

135. Quinn GP, Block RG, Clayman ML, et al. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records. J Oncol Pract 2015;11:137-144. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25549654>.

136. Salsman JM, Yanez B, Smith KN, et al. Documentation of fertility preservation discussions for young adults with cancer: examining compliance with treatment guidelines. J Natl Compr Canc Netw 2016;14:301-309. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26957616>.

137. Klosky JL, Wang F, Russell KM, et al. Prevalence and Predictors of Sperm Banking in Adolescents Newly Diagnosed With Cancer: Examination of Adolescent, Parent, and Provider Factors Influencing Fertility Preservation Outcomes. J Clin Oncol 2017;Jco2016704767. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28976795>.

138. Waimey KE, Duncan FE, Su HI, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 Oncofertility Consortium Conference. J Adolesc Young Adult Oncol 2013;2:25-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23610740>.

139. Terenziani M, Piva L, Meazza C, et al. Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril 2009;91:935 e915-936. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18951125>.

140. Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 2015;33:2424-2429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26101247>.

141. Cobo A, Kuwayama M, Perez S, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril 2008;89:1657-1664. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17889865>.

142. Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod 2010;25:2239-2246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20591872>.

143. Rienzi L, Romano S, Albricci L, et al. Embryo development of fresh 'versus' vitrified metaphase II oocytes after ICSI: a prospective randomized sibling-oocyte study. Hum Reprod 2010;25:66-73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19861328>.

144. Parmegiani L, Cognigni GE, Bernardi S, et al. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes. Reprod Biomed Online 2011;23:505-512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21843968>.

145. Cobo A, Diaz C. Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2011;96:277-285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21718983>.

146. Mature oocyte cryopreservation: a guideline. Fertility and sterility 2013;99:37-43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23083924>.

147. Salama M, Woodruff TK. New advances in ovarian autotransplantation to restore fertility in cancer patients. Cancer Metastasis Rev 2015;34:807-822. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26589603>.

148. Ladanyi C, Mor A, Christianson MS, et al. Recent advances in the field of ovarian tissue cryopreservation and opportunities for research. *J Assist Reprod Genet* 2017;34:709-722. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28365839>.

149. Dittrich R, Lotz L, Fehm T, et al. Xenotransplantation of cryopreserved human ovarian tissue--a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment. *Fertil Steril* 2015;103:1557-1565. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25881879>.

150. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA* 2011;306:269-276. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21771987>.

151. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. *Ann Oncol* 2010;21:2052-2060. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20305034>.

152. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. *J Clin Oncol* 2011;29:2334-2341. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21537042>.

153. Demeestere I, Brice P, Peccatori FA, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. *J Clin Oncol* 2013;31:903-909. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23129737>.

154. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a

randomized controlled trial. *Obstet Gynecol* 2013;121:78-86. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23262931>.

155. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med* 2015;372:923-932. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25738668>.

156. Bildik G, Akin N, Senbabaoglu F, et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. *Hum Reprod* 2015;30:2912-2925. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26466909>.

157. Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. *Oncologist* 2015;20:1283-1289. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26463871>.

158. Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. *J Clin Oncol* 2016;34:2568-2574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27217453>.

159. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. *Cancer Treat Rev* 2014;40:675-683. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24360817>.

160. Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. *Ann Oncol* 2015;26:2408-2419. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26347105>.

161. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. *JAMA Oncol* 2016;2:65-73. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26426573>.

162. Rodriguez-Wallberg K, Turan V, Munster P, Oktay K. Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients? *Ann Oncol* 2016;27:257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26609009>.

163. Oktay K, Turan V. Failure of Ovarian Suppression With Gonadotropin-Releasing Hormone Analogs to Preserve Fertility: An Assessment Based on the Quality of Evidence. *JAMA Oncol* 2016;2:74-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26426406>.

164. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. *Fertil Steril* 2011;95:906-914 e901-904. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21145541>.

165. Wang C, Chen M, Fu F, Huang M. Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis. *PLoS One* 2013;8:e66360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23805216>.

166. Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. *Breast* 2013;22:150-157. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23298851>.

167. Ben-Aharon I, Gaftor-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. *Breast Cancer*

Res Treat 2010;122:803-811. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20571868>.

168. Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. *Clin Obstet Gynecol* 2010;53:740-752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21048441>.

169. Bates JS, Buie LW, Woodis CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. *Pharmacotherapy* 2011;31:1092-1110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22026397>.

170. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. *Oncologist* 2015;20:270-278. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25673106>.

171. Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. *Ann Oncol* 2016;27:262-266. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26578736>.

172. Williams DH. Sperm banking and the cancer patient. *Ther Adv Urol* 2010;2:19-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21789080>.

173. Laurence V, Gbolade BA, Morgan SJ, Glaser A. Contraception for teenagers and young adults with cancer. *Eur J Cancer* 2004;40:2705-2716. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15571952>.

174. Murphy D, Klosky JL, Termuhlen A, et al. The need for reproductive and sexual health discussions with adolescent and young adult cancer patients. *Contraception* 2013;88:215-220. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23040131>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

175. Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group TACoOG. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. *Obstet Gynecol* 2012;120:983-988. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22996129>.

176. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. *Obstet Gynecol* 2011;117:1105-1113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21508749>.

177. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. *N Engl J Med* 2012;366:1998-2007. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22621627>.

178. Patel A, Schwarz EB, Society of Family P. Cancer and contraception. Release date May 2012. SFP Guideline #20121. *Contraception* 2012;86:191-198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22682881>.

179. Curtis KM, Tepper NK, Jatlaoui TC, et al. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. *MMWR Recomm Rep*. Vol. 65(No. RR-3); 2016:1-104. Available at: <https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6503.pdf>.

180. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. *MMWR* 2010. Vol. 59 (No. RR-4):1-85. Available at: <http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf>.

181. Pavlidis NA. Coexistence of pregnancy and malignancy. *Oncologist* 2002;7:279-287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12185292>.

182. Azim HA, Jr., Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part

II: Hematological tumors. *Cancer Treat Rev* 2010;36:110-121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20018452>.

183. Azim HA, Jr., Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. *Cancer Treat Rev* 2010;36:101-109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20015593>.

184. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. *J Clin Oncol* 2010;28:683-689. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19841323>.

185. Andersson TM, Johansson AL, Fredriksson I, Lambe M. Cancer during pregnancy and the postpartum period: A population-based study. *Cancer* 2015;121:2072-2077. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25737403>.

186. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017: National Cancer Institute, Bethesda, MD; 2017. Available at: https://seer.cancer.gov/csr/1975_2014/.

187. Weibull CE, Eloranta S, Smedby KE, et al. Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. *J Clin Oncol* 2016;34:337-344. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26668344>.

188. Kyrgidis A, Lallas A, Moscarella E, et al. Does pregnancy influence melanoma prognosis? A meta-analysis. *Melanoma Res* 2017;27:289-299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28430756>.

189. Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. *Breast Cancer Res Treat* 2016;160:347-360. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27683280>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

190. Azim HA, Jr., Santoro L, Russell-Edu W, et al. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. *Cancer Treat Rev* 2012;38:834-842. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22785217>.

191. Matsuo K, Whitman SA, Blake EA, et al. Feto-maternal outcome of pregnancy complicated by vulvar cancer: a systematic review of literature. *Eur J Obstet Gynecol Reprod Biol* 2014;179:216-223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24768232>.

192. Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010;21 Suppl 5:v266-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20555095>.

193. Lishner M, Avivi I, Apperley JF, et al. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. *J Clin Oncol* 2016;34:501-508. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26628463>.

194. Loibl S, Schmidt A, Gentilini O, et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. *JAMA Oncol* 2015;1:1145-1153. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26247818>.

195. Martin DD. Review of radiation therapy in the pregnant cancer patient. *Clin Obstet Gynecol* 2011;54:591-601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22031249>.

196. ACR-SPR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation-Revised 2013 (Resolution 48). Available at: <http://www.acr.org/Quality-Safety/Standards-Guidelines/Practice-Guidelines-by-Modality/General-Diagnostic>.

197. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. *Lancet Oncol* 2004;5:283-291. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15120665>.

198. Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. *Clin Obstet Gynecol* 2011;54:602-618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22031250>.

199. Koren G, Carey N, Gagnon R, et al. Cancer chemotherapy and pregnancy. *J Obstet Gynaecol Can* 2013;35:263-280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23470115>.

200. Pinnix CC, Osborne EM, Chihara D, et al. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. *JAMA Oncol* 2016;2:1065-1069. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27227654>.

201. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. *Am J Clin Oncol* 2010;33:221-228. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19745695>.

202. Amant F, Han SN, Gziri MM, et al. Chemotherapy during pregnancy. *Curr Opin Oncol* 2012;24:580-586. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22581358>.

203. Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. *Lancet Oncol* 2012;13:887-896. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22902483>.

204. Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *N Engl J Med* 2015;373:1824-1834. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26415085>.

205. Duggan B, Muderspach LI, Roman LD, et al. Cervical cancer in pregnancy: reporting on planned delay in therapy. *Obstet Gynecol* 1993;82:598-602. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8377988>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

206. Cold S, During M, Ewertz M, et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). *Br J Cancer* 2005;93:627-632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16136052>.

207. Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. *Lancet* 2012;379:570-579. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22325662>.

208. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. *Lancet* 2012;379:580-587. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22325663>.

209. Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. *Ann Hematol* 2015;94 Suppl 2:S167-176. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25814083>.

210. Einarson A, Maltepe C, Navioz Y, et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG* 2004;111:940-943. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15327608>.

211. Matok I, Gorodischer R, Koren G, et al. The safety of metoclopramide use in the first trimester of pregnancy. *N Engl J Med* 2009;360:2528-2535. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19516033>.

212. Zebrack B, Isaacson S. Psychosocial care of adolescent and young adult patients with cancer and survivors. *J Clin Oncol* 2012;30:1221-1226. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22412147>.

213. D'Agostino NM, Penney A, Zebrack B. Providing developmentally appropriate psychosocial care to adolescent and young adult cancer survivors. *Cancer* 2011;117:2329-2334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523754>.

214. Palmer S, Patterson P, Thompson K. A national approach to improving adolescent and young adult (AYA) oncology psychosocial care: the development of AYA-specific psychosocial assessment and care tools. *Palliat Support Care* 2014;12:183-188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23659778>.

215. Arnett JJ. Emerging adulthood. A theory of development from the late teens through the twenties. *Am Psychol* 2000;55:469-480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10842426>.

216. Zeltzer LK. Cancer in adolescents and young adults psychosocial aspects. Long-term survivors. *Cancer* 1993;71:3463-3468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8490896>.

217. Evan EE, Kaufman M, Cook AB, Zeltzer LK. Sexual health and self-esteem in adolescents and young adults with cancer. *Cancer* 2006;107:1672-1679. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16906508>.

218. Ishibashi A, Okamura J, Ueda R, et al. Psychosocial Strength Enhancing Resilience in Adolescents and Young Adults With Cancer. *J Pediatr Oncol Nurs* 2016;33:45-54. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25862715>.

219. Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock 'n' roll: caring for adolescents and young adults with cancer. *J Clin Oncol* 2010;28:4825-4830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20498401>.

220. Sleight AG, Duker LI. Toward a Broader Role for Occupational Therapy in Supportive Oncology Care. *Am J Occup Ther* 2016;70:7004360030p7004360031-7004360038. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27295001>.

221. Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. *Cancer* 2006;107:1752-1759. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16967441>.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

222. Kwak M, Zebrack BJ, Meeske KA, et al. Trajectories of Psychological Distress in Adolescent and Young Adult Patients With Cancer: A 1-Year Longitudinal Study. *Journal of Clinical Oncology* 2013;31:2160-2166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23650425>.

223. Kwak M, Zebrack BJ, Meeske KA, et al. Prevalence and predictors of post-traumatic stress symptoms in adolescent and young adult cancer survivors: a 1-year follow-up study. *Psychooncology* 2013;22:1798-1806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23135830>.

224. Zebrack BJ, Corbett V, Embry L, et al. Psychological distress and unsatisfied need for psychosocial support in adolescent and young adult cancer patients during the first year following diagnosis. *Psychooncology* 2014;23:1267-1275. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24664958>.

225. Burgoyne MJ, Bingen K, Leuck J, et al. Cancer-Related Distress in Young Adults Compared to Middle-Aged and Senior Adults. *J Adolesc Young Adult Oncol* 2015;4:56-63. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26812552>.

226. Prasad PK, Hardy KK, Zhang N, et al. Psychosocial and Neurocognitive Outcomes in Adult Survivors of Adolescent and Early Young Adult Cancer: A Report From the Childhood Cancer Survivor Study. *J Clin Oncol* 2015;33:2545-2552. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26150441>.

227. Johannsdottir IM, Karlstad O, Loge JH, et al. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. *J Adolesc Young Adult Oncol* 2016. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27841952>.

228. Kazak AE, Derosa BW, Schwartz LA, et al. Psychological outcomes and health beliefs in adolescent and young adult survivors of

childhood cancer and controls. *J Clin Oncol* 2010;28:2002-2007. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20231679>.

229. Krull KR, Huang S, Gurney JG, et al. Adolescent behavior and adult health status in childhood cancer survivors. *J Cancer Surviv* 2010;4:210-217. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20383785>.

230. Emmons K, Li FP, Whitton J, et al. Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the childhood cancer survivor study. *J Clin Oncol* 2002;20:1608-1616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11896111>.

231. Lown EA, Goldsby R, Mertens AC, et al. Alcohol consumption patterns and risk factors among childhood cancer survivors compared to siblings and general population peers. *Addiction* 2008;103:1139-1148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18554347>.

232. Cox CL, McLaughlin RA, Steen BD, Hudson MM. Predicting and modifying substance use in childhood cancer survivors: application of a conceptual model. *Oncol Nurs Forum* 2006;33:51-60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16470234>.

233. Rosenberg AR, Bona K, Ketterl T, et al. Intimacy, Substance Use, and Communication Needs During Cancer Therapy: A Report From the "Resilience in Adolescents and Young Adults" Study. *J Adolesc Health* 2017;60:93-99. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27769762>.

234. Lubman DI, Cheetham A, Yucel M. Cannabis and adolescent brain development. *Pharmacol Ther* 2015;148:1-16. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25460036>.

235. Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. *Am J Public Health* 2017;107:e1-e12. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28644037>.

236. Zebrack B, Bleyer A, Albritton K, et al. Assessing the health care needs of adolescent and young adult cancer patients and survivors. *Cancer* 2006;107:2915-2923. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17103383>.

237. Ward EJ, Henry LM, Friend AJ, et al. Nutritional support in children and young people with cancer undergoing chemotherapy. *Cochrane Database Syst Rev* 2015;8:Cd003298. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26301790>.

238. Proserpio T, Ferrari A, Veneroni L, et al. Spiritual aspects of care for adolescents with cancer. *Tumori* 2014;100:130e-135e. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25296603>.

239. Albritton K, Barr R, Bleyer A. The adolescence of young adult oncology. *Semin Oncol* 2009;36:478-488. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19835743>.

240. Kyngas H, Mikkonen R, Nousiainen EM, et al. Coping with the onset of cancer: coping strategies and resources of young people with cancer. *Eur J Cancer Care (Engl)* 2001;10:6-11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11827269>.

241. Zebrack BJ, Oeffinger KC, Hou P, Kaplan S. Advocacy skills training for young adult cancer survivors: the Young Adult Survivors Conference at Camp Mak-a-Dream. *Support Care Cancer* 2006;14:779-782. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16482447>.

242. Treadgold CL, Kuperberg A. Been there, done that, wrote the blog: the choices and challenges of supporting adolescents and young adults with cancer. *J Clin Oncol* 2010;28:4842-4849. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20351337>.

243. Love B, Crook B, Thompson CM, et al. Exploring psychosocial support online: a content analysis of messages in an adolescent and young adult cancer community. *Cyberpsychol Behav Soc Netw*

2012;15:555-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22970826>.

244. Zebrack B. Information and service needs for young adult cancer patients. *Support Care Cancer* 2008;16:1353-1360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18386075>.

245. Zebrack B. Information and service needs for young adult cancer survivors. *Support Care Cancer* 2009;17:349-357. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18543006>.

246. Palmer S, Mitchell A, Thompson K, Sexton M. Unmet needs among adolescent cancer patients: a pilot study. *Palliat Support Care* 2007;5:127-134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17578063>.

247. Fallon S, Smith J, Morgan S, et al. 'Pizza, patients and points of view': Involving young people in the design of a post registration module entitled the adolescent with cancer. *Nurse Educ Pract* 2008;8:140-147. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17919977>.

248. Rabin C, Simpson N, Morrow K, Pinto B. Behavioral and psychosocial program needs of young adult cancer survivors. *Qual Health Res* 2011;21:796-806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20705863>.

249. Kirchhoff AC, Leisenring W, Krull KR, et al. Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. *Med Care* 2010;48:1015-1025. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20940653>.

250. Keegan TH, DeRouen MC, Parsons HM, et al. Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study. *Cancer Epidemiol Biomarkers Prev* 2016;25:264-273. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26826029>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

251. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:2396-2404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19255309>.

252. Smith AW, Bellizzi KM, Keegan THM, et al. Health-Related Quality of Life of Adolescent and Young Adult Patients With Cancer in the United States: The Adolescent and Young Adult Health Outcomes and Patient Experience Study. *J Clin Oncol* 2013;31:2136-2145. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23650427>.

253. Soliman H, Agresta SV. Current issues in adolescent and young adult cancer survivorship. *Cancer Control* 2008;15:55-62. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18094661>.

254. Oeffinger KC, Tonorezos ES. The cancer is over, now what?: Understanding risk, changing outcomes. *Cancer* 2011;117:2250-2257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523742>.

255. Woodward E, Jessop M, Glaser A, Stark D. Late effects in survivors of teenage and young adult cancer: does age matter? *Ann Oncol* 2011;22:2561-2568. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21427066>.

256. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. *J Clin Oncol* 2002;20:3484-3494. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12177110>.

257. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood* 2007;109:1878-1886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17119114>.

258. Bhatia S, Armenian SH, Armstrong GT, et al. Collaborative Research in Childhood Cancer Survivorship: The Current Landscape. *J Clin Oncol* 2015;33:3055-3064. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26304891>.

259. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med* 2006;355:1572-1582. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17035650>.

260. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. *J Clin Oncol* 2009;27:2328-2338. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19332714>.

261. Tai E, Buchanan N, Townsend J, et al. Health status of adolescent and young adult cancer survivors. *Cancer* 2012;118:4884-4891. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22688896>.

262. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. *JAMA* 2013;309:2371-2381. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23757085>.

263. Zhang Y, Lorenzi MF, Goddard K, et al. Late morbidity leading to hospitalization among 5-year survivors of young adult cancer: a report of the childhood, adolescent and young adult cancer survivors research program. *Int J Cancer* 2014;134:1174-1182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24037993>.

264. Kirchhoff AC, Spraker-Perlman HL, McFadden M, et al. Sociodemographic Disparities in Quality of Life for Survivors of Adolescent and Young Adult Cancers in the Behavioral Risk Factor Surveillance System. *J Adolesc Young Adult Oncol* 2014;3:66-74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24940530>.

265. Richardson DP, Daly C, Sutradhar R, et al. Hospitalization Rates Among Survivors of Young Adult Malignancies. *J Clin Oncol* 2015;33:2655-2659. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26169617>.

266. Rugbjerg K, Olsen JH. Long-term Risk of Hospitalization for Somatic Diseases in Survivors of Adolescent or Young Adult Cancer.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

JAMA Oncol 2016;2:193-200. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26584448>.

267. Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006. 2006. Available at:
http://seer.cancer.gov/publications/mpmono/MPMonograph_complete.pdf.

268. Turcotte LM, Whitton JA, Friedman DL, et al. Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort. J Clin Oncol 2015;33:3568-3575. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26261260>.

269. Lee JS, DuBois SG, Coccia PF, et al. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer 2016;122:116-123. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26441212>.

270. Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008;14:429-434. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19060610>.

271. Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010;20:67-78. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19959033>.

272. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-1095. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20634481>.

273. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/12837833>.

274. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16204692>.

275. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010;152:444-455; W144-454. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20368650>.

276. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11830608>.

277. Swerdlow AJ, Higgins CD, Smith P, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncol 2011;29:4096-4104. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21969511>.

278. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114-1130. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20585105>.

279. Gilligan T. Testicular cancer survivorship. Hematol Oncol Clin North Am 2011;25:627-639, x. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21570614>.

280. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-1066. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16030303>.

281. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl

Cancer Inst 2005;97:1354-1365. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16174857>.

282. Wierecky J, Kollmannsberger C, Boehlke I, et al. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol 2005;131:255-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15627215>.

283. Howard R, Gilbert E, Lynch CF, et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol 2008;18:416-421. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18433667>.

284. Chaturvedi AK, Engels EA, Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-1643. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971527>.

285. Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007;106:439-451. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17277968>.

286. Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 2008;26:1850-1857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18347006>.

287. Effinger KE, Migliorati CA, Hudson MM, et al. Oral and dental late effects in survivors of childhood cancer: a Children's Oncology Group report. Support Care Cancer 2014;22:2009-2019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24781353>.

288. Perkins SM, Dewees T, Shinohara ET, et al. Risk of subsequent malignancies in survivors of childhood leukemia. J Cancer Surviv 2013;7:544-550. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23749687>.

289. Ginsberg JP, Goodman P, Leisenring W, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010;102:1272-1283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20656964>.

290. Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer 2011;117:625-634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20922787>.

291. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 4.0.; 2013. Available at: www.survivorshipguidelines.org.

292. Mulder RL, Kremer LC, Hudson MM, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2013;14:e621-629. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24275135>.

293. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 2011;108:619-628. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21372293>.

294. Kero AE, Jarvela LS, Arola M, et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer 2014;134:664-673. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23852751>.

295. Rugbjerg K, Mellekjaer L, Boice JD, et al. Cardiovascular disease in survivors of adolescent and young adult cancer: a Danish cohort study, 1943-2009. J Natl Cancer Inst 2014;106:dju110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24848622>.

296. van Laar M, Feltbower RG, Gale CP, et al. Cardiovascular sequelae in long-term survivors of young peoples' cancer: a linked

cohort study. Br J Cancer 2014;110:1338-1341. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24504369>.

297. Chao C, Xu L, Bhatia S, et al. Cardiovascular Disease Risk Profiles in Survivors of Adolescent and Young Adult (AYA) Cancer: The Kaiser Permanente AYA Cancer Survivors Study. J Clin Oncol 2016;34:1626-1633. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26951318>.

298. Scholz-Kreisel P, Spix C, Blettner M, et al. Prevalence of cardiovascular late sequelae in long-term survivors of childhood cancer: A systematic review and meta-analysis. Pediatr Blood Cancer 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28205419>.

299. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999;51:35-42. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/10386715>.

300. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-214. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17284715>.

301. Feijen EA, Leisenring WM, Stratton KL, et al. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol 2015;33:3774-3780. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26304888>.

302. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011;Cd003917. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21678342>.

303. Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review

and Meta-Analysis. J Natl Cancer Inst 2016;108. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26598513>.

304. Asselin BL, Devidas M, Chen L, et al. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol 2016;34:854-862. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26700126>.

305. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-475. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/16421423>.

306. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649-4657. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20855830>.

307. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 2011;60:516-526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21684072>.

308. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19996459>.

309. Amini A, Murphy B, Cost CR, et al. Cardiac Mortality in Children and Adolescents with Hodgkin's Lymphoma: A Surveillance, Epidemiology and End Results Analysis. J Adolesc Young Adult Oncol 2016;5:181-186. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26959398>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

310. Dietz AC, Chen Y, Yasui Y, et al. Risk and impact of pulmonary complications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *Cancer* 2016;122:3687-3696. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27504874>.

311. Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. *Cancer* 2002;95:2431-2441. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12436452>.

312. Huang TT, Chen Y, Dietz AC, et al. Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer* 2014;61:319-325. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24127436>.

313. Fossa SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. *J Natl Cancer Inst* 2007;99:533-544. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17405998>.

314. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. *Ann Oncol* 2003;14:91-96. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12488299>.

315. Haugnes HS, Aass N, Fossa SD, et al. Pulmonary function in long-term survivors of testicular cancer. *J Clin Oncol* 2009;27:2779-2786. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19414680>.

316. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. *J Clin Oncol* 2009;27:2339-2355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19364955>.

317. Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. *J Clin Oncol* 2003;21:3255-3261. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12947060>.

318. Bass JK, Hua CH, Huang J, et al. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer. *J Clin Oncol* 2016;34:1248-1255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26811531>.

319. Brinkman TM, Krasin MJ, Liu W, et al. Long-Term Neurocognitive Functioning and Social Attainment in Adult Survivors of Pediatric CNS Tumors: Results From the St Jude Lifetime Cohort Study. *J Clin Oncol* 2016;34:1358-1367. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26834063>.

320. Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. *J Natl Cancer Inst* 2009;101:1682-1695. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19940282>.

321. Boyette-Davis JA, Cata JP, Driver LC, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. *Cancer Chemother Pharmacol* 2013;71:619-626. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23228992>.

322. Jain P, Gulati S, Seth R, et al. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. *J Child Neurol* 2014;29:932-937. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23781018>.

323. Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. *J Peripher Nerv Syst* 2009;14:184-189. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19909482>.

324. Mustafa Ali M, Moeller M, Rybicki L, Moore HCF. Long-term peripheral neuropathy symptoms in breast cancer survivors. *Breast Cancer Res Treat* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28791499>.

325. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005;23:6508-6515. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16170160>.

326. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006;24:5277-5282. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17088567>.

327. Fullerton HJ, Stratton K, Mueller S, et al. Recurrent stroke in childhood cancer survivors. Neurology 2015;85:1056-1064. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26311747>.

328. De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928-937. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19535773>.

329. Donovan KA, Boyington AR, Judson PL, Wyman JF. Bladder and bowel symptoms in cervical and endometrial cancer survivors. Psychooncology 2014;23:672-678. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24481859>.

330. Lind H, Alevronta E, Steineck G, et al. Defecation into clothing without forewarning and mean radiation dose to bowel and anal-sphincter among gynecological cancer survivors. Acta Oncol 2016;55:1285-1293. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27173757>.

331. Alevronta E, Lind H, Al-Abany M, et al. Dose-response relationships for an atomized symptom of fecal incontinence after gynecological radiotherapy. Acta Oncol 2013;52:719-726. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23113592>.

332. Sunesen KG, Norgaard M, Lundby L, et al. Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for

anal cancer: a Danish multicentre cross-sectional questionnaire study. Colorectal Dis 2015;17:O230-239. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26218674>.

333. Mostoufi-Moab S, Seidel K, Leisenring WM, et al. Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2016;34:3240-3247. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27382091>.

334. Chow EJ, Friedman DL, Stovall M, et al. Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2009;53:432-437. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19459201>.

335. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010;174:741-752. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21128798>.

336. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200-207. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15999104>.

337. Greenberg ML. When Do Late Effects in Childhood Cancer Survivors Cease Emerging? The Endocrine Answer. J Clin Oncol 2016;34:3231-3232. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27480146>.

338. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008;121:e387-396. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18187811>.



NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

339. Liles A, Blatt J, Morris D, et al. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. *Cleve Clin J Med* 2008;75:531-539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18646589>.

340. Freyer DR. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. *J Clin Oncol* 2010;28:4810-4818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20351333>.

341. Nathan PC, Hayes-Lattin B, Sisler JJ, Hudson MM. Critical issues in transition and survivorship for adolescents and young adults with cancers. *Cancer* 2011;117:2335-2341. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523755>.

342. Sadak KT, Dinofia A, Reaman G. Patient-perceived facilitators in the transition of care for young adult survivors of childhood cancer. *Pediatr Blood Cancer* 2013;60:1365-1368. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23441065>.

343. Oeffinger KC, McCabe MS. Models for delivering survivorship care. *J Clin Oncol* 2006;24:5117-5124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17093273>.

344. Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. *J Clin Oncol* 2008;26:1073-1079. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18309941>.

345. Blaauwbroek R, Tuinier W, Meyboom-de Jong B, et al. Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. *Lancet Oncol* 2008;9:232-238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18282804>.

346. Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with

controls: changes from 1998 to 2002. *J Clin Oncol* 2009;27:1054-1061. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19164212>.

347. Wallace WH, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. *BMJ* 2001;323:271-274. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11485960>.

348. Oeffinger KC. Longitudinal risk-based health care for adult survivors of childhood cancer. *Curr Probl Cancer* 2003;27:143-167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12748583>.

349. Wein S, Pery S, Zer A. Role of palliative care in adolescent and young adult oncology. *J Clin Oncol* 2010;28:4819-4824. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20212259>.

350. Rosenberg AR, Wolfe J. Palliative care for adolescents and young adults with cancer. *Clinical Oncology in Adolescents and Young Adults* 2013;2013:41-48. Available at: <https://www.dovepress.com/palliative-care-for-adolescents-and-young-adults-with-cancer-peer-reviewed-article-COAYA>.

351. Wiener L, Weaver MS, Bell CJ, Sansom-Daly UM. Threading the cloak: palliative care education for care providers of adolescents and young adults with cancer. *Clin Oncol Adolesc Young Adults* 2015;5:1-18. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25750863>.

352. Pritchard S, Cuvelier G, Harlos M, Barr R. Palliative care in adolescents and young adults with cancer. *Cancer* 2011;117:2323-2328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21523753>.

353. Lyon ME, McCabe MA, Patel KM, D'Angelo LJ. What do adolescents want? An exploratory study regarding end-of-life decision-making. *J Adolesc Health* 2004;35:529 e521-526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15581537>.

354. Wiener L, Zadeh S, Wexler LH, Pao M. When silence is not golden: Engaging adolescents and young adults in discussions around



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2018

Adolescent and Young Adult Oncology

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

end-of-life care choices. *Pediatric Blood & Cancer* 2013;60:715-718.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23483724>.

355. Mack JW, Chen LH, Cannavale K, et al. End-of-Life Care Intensity Among Adolescent and Young Adult Patients With Cancer in Kaiser Permanente Southern California. *JAMA Oncol* 2015;1:592-600.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26181778>.

356. Webb NM, Tucker D. Young adults' opinions about hospice and home death. *J Palliat Med* 2009;12:337-342. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19327070>.

357. Bell CJ, Skiles J, Pradhan K, Champion VL. End-of-life experiences in adolescents dying with cancer. *Support Care Cancer* 2010;18:827-835. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19727847>.

358. Wiener L, Ballard E, Brennan T, et al. How I wish to be remembered: the use of an advance care planning document in adolescent and young adult populations. *J Palliat Med* 2008;11:1309-1313. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19115889>.